{"id":2777,"date":"2018-06-29T01:00:00","date_gmt":"2018-07-27T06:39:41","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/07\/27\/%e7%94%9f%e5%91%bd%e7%a7%91%e5%ad%a6%e9%a2%86%e5%9f%9f%e5%80%bc%e5%be%97%e5%85%b3%e6%b3%a8%e7%9a%84%e6%8e%88%e6%9d%83%e4%ba%a4%e6%98%93%e8%ae%b8%e5%8f%af2018%e5%b9%b4%e7%ac%ac%e4%b8%80%e5%ad%a3\/"},"modified":"2018-07-27T14:39:43","modified_gmt":"2018-07-27T06:39:43","slug":"%e7%94%9f%e5%91%bd%e7%a7%91%e5%ad%a6%e9%a2%86%e5%9f%9f%e5%80%bc%e5%be%97%e5%85%b3%e6%b3%a8%e7%9a%84%e6%8e%88%e6%9d%83%e4%ba%a4%e6%98%93%e8%ae%b8%e5%8f%af2018%e5%b9%b4%e7%ac%ac%e4%b8%80%e5%ad%a3","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/2777\/","title":{"rendered":"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6"},"content":{"rendered":"
\n

\u539f\u6587\u4f5c\u8005\uff1a<\/span>Elisabet Cruces<\/span><\/strong>
<\/span><\/p>\n

<\/span><\/p>\n

\n

\u4e2d\u6587\u7ffb\u8bd1\uff1a\u8df5\u884c\u8005<\/strong><\/span>
<\/p>\n


<\/strong><\/span><\/p>\n

\n
\n
\n
\n
<\/section>\n
\n
\n

\u7b80\u4ecb<\/strong><\/p>\n<\/section>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

<\/span>2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\uff0cCortellis<\/span>\u7ade\u4e89\u60c5\u62a5\uff08Cortellis Competitive Intelligence<\/span>\uff09\u6c47\u603b\u4e86879<\/span>\u7b14\u65b0\u4ea4\u6613(<\/span><\/span>\u4e0d\u5305\u62ec\u5e76\u8d2d)\uff0c\u62ab\u9732\u7684\u4ea4\u6613\u603b\u989d\u7ea6\u4e3a352\u4ebf\u7f8e\u5143\uff0c\u8fd9\u53ea\u662f\u5176\u5728\u751f\u547d\u79d1\u5b66\u9886\u57df\u6301\u7eed\u8fdb\u884c\u4f7f\u7528\u8bb8\u53ef\u4ea4\u6613\u6d3b\u52a8\u7684\u4e00\u90e8\u5206\u3002<\/span>\u76f8\u6bd4\u4e4b\u4e0b\uff0c2017<\/span>\u5e74\u7b2c\u56db\u5b63\u5ea6\u4ea4\u6613\u7b14\u6570\u4e3a1,203<\/span>\u7b14\uff0c\u4ea4\u6613\u91d1\u989d\u4e3a262<\/span>\u4ebf\u7f8e\u5143\uff1b2017<\/span>\u5e74\u7b2c\u4e00\u5b63\u5ea6\u4e3a1,158<\/span>\u7b14\u4ea4\u6613\uff0c\u4ea4\u6613\u91d1\u989d\u4e3a318<\/span>\u4ebf\u7f8e\u5143\u3002\u8fd9\u610f\u5473\u7740\uff0c\u4e0e\u524d\u4e24\u671f\u76f8\u6bd4\uff0c\u8be5\u516c\u53f8\u62ab\u9732\u7684\u4ea4\u6613\u603b\u4ef7\u503c\u5927\u5e45\u589e\u52a0(<\/span>\u5206\u522b\u589e\u52a034%<\/span>\u548c10.7%)<\/span>\uff0c\u5176\u4e2d\u5305\u62ec\u9ed8\u514b\u516c\u53f8\u548c\u65e5\u672c\u536b\u6750\u516c\u53f8\u4e4b\u95f4\u768458<\/span>\u4ebf\u7f8e\u5143\u7684\u534f\u8bae\uff0c\u8be5\u534f\u8bae\u6210\u4e3a\u8fc7\u53bb4<\/span>\u5e74\u7684\u9996\u5b63\u6700\u9ad8\u4ea4\u6613\u989d\u3002\u7136\u800c\uff0c\u4e0e2017<\/span>\u5e74\u7b2c\u56db\u5b63\u5ea6\u548c2017<\/span>\u5e74\u7b2c\u4e00\u5b63\u5ea6\u76f8\u6bd4\uff0c2018<\/span>\u5e74\u7b2c\u4e00\u5b63\u5ea6\u7b7e\u7f72\u7684\u534f\u8bae\u6570\u91cf\u5e76\u4e0d\u9ad8\uff08(<\/span>\u5206\u522b\u51cf\u5c1127%<\/span>\u548c24%)<\/span>\uff09\uff0c\u4e0e\u534f\u8bae\u603b\u6570\u4e3a931<\/span>\u4e2a\u76842014<\/span>\u5e74\u7b2c\u4e00\u5b63\u5ea6\u7684\u6570\u636e\u7c7b\u4f3c (<\/span>\u89c1\u56fe1)<\/span>\u3002<\/span><\/o:p><\/span><\/p>\n


<\/span><\/p>\n

\u7b2c\u4e00\u5b63\u5ea6\u516c\u5e03\u7684\u8bb8\u53ef\u534f\u8bae(2010-2018\u5e74)<\/span><\/strong><\/span><\/p>\n

<\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

<\/span><\/p>\n

\u56fe1: 2010-2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u7684\u4ea4\u6613\u6d3b\u52a8 (\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/em><\/span><\/p>\n


<\/span><\/p>\n

\u4e70\u65b9\/\u5356\u65b9\u62ab\u9732\u7684\u4ea4\u6613<\/span><\/strong><\/span><\/p>\n

<\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

<\/span>\u56fe2\uff1a\u6839\u636e\u62ab\u9732\u7684\u4ea4\u6613\u89c4\u6a21\u7cbe\u9009\u51fa\u76842018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u7684\u9876\u7ea7\u4ea4\u6613(\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/em><\/span><\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n
\n

\u4ef7\u503c\u8d85\u8fc75\u4ebf\u7f8e\u5143\u7684\u9ad8\u503c\u4ea4\u6613<\/strong><\/span><\/p>\n<\/section>\n

\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\uff0c\u6211\u4eec\u8ffd\u8e2a\u4e8648\u7b14\u4ef7\u503c\u8d85\u8fc71\u4ebf\u7f8e\u5143\u7684\u9ad8\u503c\u65b0\u8bb8\u53ef\u534f\u8bae\u3002\u4ee5\u4e0b\u662f\u4e00\u4e9b\u4ef7\u503c\u8d85\u8fc75\u4ebf\u7f8e\u5143\u7684\u4ea4\u6613\uff0c\u8fd9\u4e9b\u4ea4\u6613\u5927\u591a\u662f\u91c7\u7528\u5206\u671f\u4ed8\u6b3e\u65b9\u5f0f\uff0c\u6709\u4e09\u4efd\u4e0d\u540c\u7684\u534f\u8bae\u4ef7\u503c\u9ad8\u8fbe30\u4ebf\u7f8e\u5143(\u89c1\u56fe2)\u3002<\/span><\/p>\n

 <\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u9ed8\u514b\u516c\u53f8(Merck)\u548c\u536b\u6750\u516c\u53f8(Eisai)\u8fbe\u6210\u4e8658\u4ebf\u7f8e\u5143\u7684\u80bf\u7624\u836f\u5408\u4f5c\u534f\u8bae\uff0c\u5c06\u4e50\u4f10\u66ff\u5c3c\uff08lenvatinib\uff09\u548cpembrolizumab\u8054\u7528<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

 
<\/span><\/p>\n

\u65e5\u672c\u536b\u6750\uff08Eisai\uff09\u516c\u53f8\u548c\u7f8e\u56fd\u9ed8\u514b\u516c\u53f8(MSD)\u540c\u610f\u5171\u540c\u5f00\u53d1\u548c\u63a8\u5e7f\u536b\u6750\u516c\u53f8\u7684\u7532\u78fa\u9178\u4e50\u4f10\u66ff\u5c3c\uff08lenvatinibmesylate\uff09\uff0c\u7532\u78fa\u9178\u4e50\u4f10\u66ff\u5c3c\u662f\u4e00\u79cd\u5305\u62ecKit\/Kdr\u3001RET\u548cPDGFR beta\u5728\u5185\u7684\u591a\u79cd\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u4ee5\u53ca\u7f8e\u56fd\u9ed8\u514b\u516c\u53f8\u7684pembrolizumab\uff0cpembrolizumab\u662f\u6297\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\u86cb\u767d\u914d\u4f531 (PD-1)\uff0c\u4f5c\u4e3a\u5355\u514b\u9686\u6297\u4f53\u6700\u521d\u7528\u4e8e\u6cbb\u7597\u80be\u7ec6\u80de\u764c(\u76ee\u524d\u5904\u4e8e3\u671f\uff0c\u83b7\u5f97\u7f8e\u56fdFDA\u7684\u201c\u7a81\u7834\u6027\u7597\u6cd5\u8ba4\u5b9a\u201d)\uff0c\u5e76\u8ba1\u5212\u5f00\u53d1\u5176\u5b83\u516d\u79cd\u80bf\u7624\u9002\u5e94\u75c7\uff0c\u5305\u62ec\u5b50\u5bab\u5185\u819c\u764c\u548c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u30022015\u5e74\uff0c\u4e24\u5bb6\u516c\u53f8\u5df2\u7ecf\u7b7e\u7f72\u4e86\u4e00\u9879\u5408\u4f5c\u534f\u8bae\uff0c\u5bf9\u4e24\u79cd\u6cbb\u7597\u5b50\u5bab\u5185\u819c\u764c\u7684\u836f\u7269\u8fdb\u884c\u8bc4\u4f30\u3002\u6839\u636e\u8fd9\u9879\u65b0\u5408\u540c\uff0c\u536b\u6750\u5c06\u83b7\u5f973\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\uff0c\u9ad8\u8fbe6.5\u4ebf\u7f8e\u5143\u7684\u671f\u6743\uff0c4.5\u4ebf\u7f8e\u5143\u7684\u7814\u53d1\u8d39\u7528\uff0c\u4ee5\u53ca\u9ad8\u8fbe43.55\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u3002<\/span><\/p>\n

 <\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff08BMS\uff09\u548c\u7f8e\u56fd\u751f\u7269\u5236\u836f\u516c\u53f8\u5185\u514b\u5854\uff08Nektar\uff09\u4e4b\u95f4\u7684\u6297\u764cNKTR-214\u548cnivolumab\u7597\u6cd5\u8054\u5408\u7528\u836f\u5408\u4f5c\uff0c\u5408\u4f5c\u91d1\u989d\u8fbe36.3\u4ebf\u7f8e\u5143<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n

 <\/p>\n

\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d(BMS)\u548c\u5185\u514b\u5854\uff08Nektar\uff09\u7b7e\u7f72\u4e86\u672c\u5b63\u5ea6\u7b2c\u4e8c\u4efd\u80bf\u7624\u5b66\u9ad8\u4ef7\u503c\u534f\u8bae\uff0c\u5171\u540c\u5f00\u53d1\u5185\u514b\u5854\u516c\u53f8\uff08Nektar\uff09\u7684NKTR-214\u548c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff08BMS\uff09\u7684nivolumab\uff0cNKTR-214\u662f\u4e00\u6b3e\u5728\u7814CD122\u504f\u501a\u53d7\u4f53\u6fc0\u52a8\u5242\uff0c\u800cnivolumab\u662f\u4e00\u79cd\u5b8c\u5168\u6297\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\uff08PD\uff09-1\u6297\u4f53\uff0c\u6216nivolumab \u548cipilimumab\u8054\u5408\u7528\u836f\uff0c\u8fd9\u662f\u4e00\u6b3e\u9759\u8109\u514d\u75ab\u523a\u6fc0\u6027\u4eba\u7c7b\u5355\u514b\u9686\u6297\u4f53\uff0c\u80fd\u6709\u6548\u963b\u6ede\u4e00\u79cd\u53eb\u505a\u7ec6\u80de\u6bd2\u6027T\u7ec6\u80de\u6297\u539f-4\u7684\u5206\u5b50\uff0c\u9002\u7528\u4e8e\u5305\u62ec\u9ed1\u8272\u7d20\u7624\u548c\u80be\u7ec6\u80de\u764c\u5728\u5185\u76849\u79cd\u80bf\u7624\u768420\u79cd\u9002\u5e94\u75c7\u3002\u6b64\u524d\uff0c\u57282016\u5e74\uff0c\u4e24\u5bb6\u516c\u53f8\u5df2\u7ecf\u5bf9\u8fd9\u4e24\u79cd\u836f\u7269\u8fdb\u884c\u4e865\u79cd\u80bf\u7624\u7c7b\u578b\u548c7\u79cd\u80bf\u7624\u9002\u5e94\u75c7\u7684\u8bc4\u4f30\u3002Nektar\u6536\u5230\u4e8618.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e(10\u4ebf\u7f8e\u5143\u73b0\u91d1\uff0c\u5269\u4f59\u7684\u4e3a\u80a1\u7968)\uff0c\u4ee5\u53ca\u9ad8\u8fbe17.8\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u3002<\/span><\/p>\n

<\/span><\/p>\n

\n

<\/span>
<\/p>\n

<\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u5409\u5229\u5fb7\uff08Gilead\uff09\u65d7\u4e0b\u516c\u53f8 Kite\u4e0eSangamo\u8054\u624b\u6253\u9020\u4ef7\u503c31.6\u4ebf\u7f8e\u5143\u7684\u80bf\u7624\u5de5\u7a0b\u7ec6\u80de\u7597\u6cd5\u5408\u4f5c\u9879\u76ee<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/span><\/p>\n

Sangamo\u7684\u950c\u6307\u6838\u9178\u9176(ZFN)\u6280\u672f\u5438\u5f15\u4e86\u5409\u5229\u5fb7\u65d7\u4e0b\u5b50\u516c\u53f8Kite Pharma\u7684\u773c\u7403\uff0c\u6b32\u7528\u6b64\u9879\u6280\u672f\u5f00\u53d1\u6297\u764c\u7684\u5de5\u7a0b\u7ec6\u80de\u7597\u6cd5\u3002\u53cc\u65b9\u5c06\u7814\u7a76\u7528ZFNs\u548c\u817a\u76f8\u5173\u75c5\u6bd2(AAVs)\uff0c\u5728T\u7ec6\u80de\u548cNK\u7ec6\u80de\u4e2d\u5206\u88c2\u548c\u63d2\u5165\u67d0\u4e9b\u57fa\u56e0\uff0c\u5305\u62ec\u9488\u5bf9\u53cc\u65b9\u5546\u5b9a\u7684\u9776\u5411\uff0c\u63d2\u5165\u7f16\u7801\u5d4c\u5408\u6297\u539f\u53d7\u4f53(CARs)\u3001T\u7ec6\u80de\u53d7\u4f53(TCRs)\u548cNK\u7ec6\u80de\u53d7\u4f53(NKRs)\u7684\u57fa\u56e0\u3002Sangamo\u83b7\u5f97\u4e861.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\uff0c\u5e76\u6709\u8d44\u683c\u83b7\u5f97\u6700\u9ad830.1\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n

<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/em><\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

Sangamo\u7684\u950c\u6307\u6838\u9178\u9176(ZFN)\u6280\u672f\u5438\u5f15\u4e86\u5409\u5229\u5fb7\u65d7\u4e0b\u5b50\u516c\u53f8Kite Pharma\u7684\u773c\u7403\uff0c\u6b32\u7528\u8be5\u6280\u672f\u5f00\u53d1\u6297\u764c\u7684\u5de5\u7a0b\u7ec6\u80de\u7597\u6cd5\u3002<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

Celgene\u516c\u53f8\u4ee522.6\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97\u4e86Prothena\u7684\u795e\u7ecf\u9000\u884c\u6027\u6297\u4f53\u7684\u671f\u6743<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u6839\u636e\u5176\u671f\u6743\u7b56\u7565\uff0cCelgene\u516c\u53f8\u786e\u4fdd\u4e86Prothena\u7684\u6297\u4f53\u5728\u4e16\u754c\u8303\u56f4\u5185\u7684\u6f5c\u5728\u6743\u5229\uff0c\u8fd9\u4e9b\u6297\u4f53\u9488\u5bf9\u4e09\u79cd\u86cb\u767d\uff0c\u5305\u62ectau\u86cb\u767d\u3001TDP-43\u86cb\u767d\uff0c\u4ee5\u53ca\u4e00\u4e2a\u672a\u516c\u5f00\u7684\u80fd\u6cbb\u7597\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u7684\u6f5c\u5728\u9776\u70b9\uff0c\u5305\u62ec\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u548c\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7\u3002Prothena\u83b7\u5f97\u4e861.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e(1\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u73b0\u91d1\u548c5000\u4e07\u7f8e\u5143\u7684\u80a1\u7968)\u30014.25\u4ebf\u7f8e\u5143\u7684\u671f\u6743\u548c\u5ef6\u671f\u8d39\uff0c\u4ee5\u53ca16.87\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/o:p><\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u6b66\u7530\u5b8c\u6210\u4ef7\u683c\u4e3a22.3\u4ebf\u7f8e\u5143\u7684Wave Life\u516c\u53f8\u7684\u53cd\u4e49\u5be1\u6838\u82f7\u9178\u548c\u4ef7\u683c\u4e3a17.2\u4ebf\u7f8e\u5143\u7684\u5fb7\u7eb3\u5229\u516c\u53f8\uff08Denali\uff09\u7684\u6297\u4f53\u9012\u9001\u8f7d\u4f53\uff08ATV\uff09\u6280\u672f\u4e24\u6869\u4ea4\u6613\uff0c\u6269\u5c55\u5176\u5728\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\uff08CNS\uff09\u7684\u6295\u8d44\u7ec4\u5408<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n


<\/p>\n

\u65e5\u672c\u6b66\u7530\u5236\u836f\u516c\u53f8\u5728\u4e16\u754c\u8303\u56f4\u5185\u83b7\u5f97\u4e86Wave\u751f\u547d\u79d1\u5b66\u516c\u53f8\u7684\u53cd\u4e49\u5be1\u6838\u82f7\u9178\u7684\u671f\u6743\uff0c\u5176\u4e2d\u5305\u62ecWVE-120101\u3001WVE-120102\u3001WVE-3972-01\u548c\u4e00\u4e2a\u9776\u5411ATXN3\u57fa\u56e0\u6cbb\u7597\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u75be\u75c5\u7684\u9879\u76ee\u548c\u82e5\u5e72\u4e2a\u6cbb\u7597\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u548c\u5e15\u91d1\u68ee\u6c0f\u75c7\u7684\u4e34\u5e8a\u524d\u9879\u76ee\u3002\u8fd9\u5bb6\u65e5\u672c\u516c\u53f8\u5c06\u652f\u4ed81.7\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e(1.1\u4ebf\u7f8e\u5143\u7684\u73b0\u91d1\u548c6000\u4e07\u7f8e\u5143\u7684\u80a1\u7968)\u30016000\u4e07\u7f8e\u5143\u7684\u7814\u53d1\u8d44\u91d1\u548c\u9ad8\u8fbe20\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/o:p><\/span><\/p>\n


<\/span><\/p>\n

\u4e0e\u6b64\u540c\u65f6\uff0c\u6b66\u7530\u4e5f\u83b7\u5f97\u4e86\u5f00\u53d1\u5fb7\u7eb3\u5229\u516c\u53f8\uff08Denali\uff09\u7684\u4e09\u4e2a\u9879\u76ee\u7684\u9009\u62e9\u6743\uff0c\u5305\u62ecATV:BACE1\/Tau, ATV:TREM2\u548c\u7b2c\u4e09\u4e2a\u5df2\u786e\u5b9a\u7684\u672a\u516c\u5f00\u9879\u76ee\uff0c\u901a\u8fc7Denali\u7684\u6297\u4f53\u4f20\u8f93\u8f7d\u4f53(ATV)\u6280\u672f\u6765\u589e\u52a0\u8840\u8111\u5c4f\u969c(BBB)\u6e17\u900f\uff0c\u7528\u4e8e\u6cbb\u7597\u5305\u62ec\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u5728\u5185\u7684\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u3002\u5fb7\u7eb3\u5229\u5c06\u83b7\u5f971.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u91d1(1.1\u4ebf\u7f8e\u5143\u73b0\u91d1\u548c4000\u4e07\u7f8e\u5143\u80a1\u7968)\uff0c1500\u4e07\u7f8e\u5143\u7684\u671f\u6743\u8d39\u548c\u9ad8\u8fbe10.1\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

Akcea\u4ee518.8\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97\u4e86\u6bcd\u516c\u53f8Ionis\u7684inotersen\u548cAKCEA-TTR-LRx\u4e24\u9879\u836f\u7269\u7684\u5f00\u53d1\u63a8\u5e7f\u6743\uff0c\u540e\u8005\u7528\u4e8e\u6cbb\u7597\u9057\u4f20\u6027\u7532\u72b6\u817a\u7d20\u8fd0\u8f7d\u86cb\u767d\u6dc0\u7c89\u6837\u53d8\u6027\uff08hATTR\uff09<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n


<\/span><\/p>\n

Akcea\u662fIonis 75%\u80a1\u6743\u7684\u5b50\u516c\u53f8\uff0c\u8be5\u516c\u53f8\u4ece\u6bcd\u516c\u53f8\u83b7\u5f97inotersen\u5728\u5168\u7403\u7684\u6743\u5229\uff0c\u6709\u671b\u4e8e2018\u5e74\u83b7\u5f97\u6279\u51c6\uff1bAKCEA-TTR-LRx\u4e5f\u8ba1\u5212\u5728\u4eca\u5e74\u8fdb\u884c\u4e34\u5e8a\u5f00\u53d1\uff0c\u7528\u4e8e\u6cbb\u7597\u9057\u4f20\u6027\u8f6c\u7532\u72b6\u817a\u7d20\u86cb\u767d\u6dc0\u7c89\u6837\u53d8\u6027\uff08hATTR\uff09\u3002Ionis\u5c06\u83b7\u5f971.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\uff0c\u4ee5\u53ca\u9ad8\u8fbe15.3\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e(\u89c1\u56fe3)\u3002<\/span><\/o:p><\/p>\n

<\/span>
<\/p>\n

<\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

<\/span><\/p>\n

\u56fe3\uff1aIonis\u4e0eAkea\u5408\u4f5c\u5f00\u53d1inotersen\u548c\u7528\u4e8e\u6cbb\u7597hATTR\u7684AKCEA-TTR- LRx(\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/o:p><\/span><\/p>\n

<\/span><\/p>\n

 <\/span><\/p>\n

<\/span><\/em><\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

Ionis\u5c06\u83b7\u5f971.5\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u548c\u9ad8\u8fbe 15.3\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

 <\/p>\n

\n
\n
\n
\n
\n
\n
\n

Pieris\u7684Anticalin\u6297\u764c\u6280\u672f\u5f15\u8d77\u4e86Seattle Genetics\u7684\u5173\u6ce8\uff0c\u5e76\u4ee512.3\u4ebf\u7f8e\u5143\u6210\u4ea4<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/span><\/p>\n

Seattle Genetics \u516c\u53f8\u83b7\u5f97\u4e86Pieris Pharmaceuticals\u516c\u53f8\u7684Anticalin\u6280\u672f\u7684\u975e\u72ec\u5bb6\u5168\u7403\u6388\u6743\uff0c\u8be5\u6280\u672f\u5c06\u5f00\u53d1\u9488\u5bf9\u5b9e\u4f53\u7624\u548c\u8840\u6db2\u764c\u7684\u65b0\u578b\u53cc\u7279\u5f02\u6027\u6297\u4f53-Anticalin\u878d\u5408\u86cb\u767d\u3002\u8be5\u516c\u53f8\u8fd8\u83b7\u5f97\u4e86\u4e00\u9879\u9009\u62e9\u6743\uff0c\u4ee53,000\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u548c\u591a\u8fbe12\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u53ca\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\uff0c\u53ef\u9009\u62e9\u6700\u591a\u4e09\u4e2a\u9879\u76ee\u3002<\/span><\/o:p><\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u827e\u4f2f\u7ef4\uff08AbbVie\uff09\u4ee517.9\u4ebf\u7f8e\u5143\u83b7\u5f97Voyager\u516c\u53f8\u7684\u9488\u5bf9\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u7684\u57fa\u56e0\u6cbb\u7597\u5e73\u53f0<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n


<\/span><\/p>\n

<\/span>AbbVie\u548cVoyager\u5c06\u5229\u7528Voyager\u7684\u57fa\u56e0\u6cbb\u7597\u5e73\u53f0\uff0c\u5171\u540c\u5f00\u53d1\u76f4\u63a5\u9488\u5bf9tau\u86cb\u767d\u7684\u817a\u76f8\u5173\u75c5\u6bd2(AAV)\u8f7d\u4f53\u6297\u4f53\uff0c\u4ee5\u6cbb\u7597\u963f\u5c14\u8328\u6d77\u9ed8\u75c7\u548c\u5176\u5b83\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u3002Voyager\u83b7\u5f97\u4e866900\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u8d39\u7528\u30017500\u4e07\u7f8e\u5143\u7684\u671f\u6743\u8d39\u548c\u591a\u8fbe10.35\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u53ca\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n

<\/span><\/p>\n


<\/span><\/em><\/h2>\n


<\/span><\/em><\/p>\n

<\/span><\/em><\/h2>\n
\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

Voyager\u83b7\u5f97\u4e866900\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u30017500\u4e07\u7f8e\u5143\u7684\u671f\u6743\u8d39\u548c\u9ad8\u8fbe10.35\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u53ca\u7279\u8bb8\u6743\u4f7f\u7528\u8d39 <\/strong><\/span><\/p>\n


<\/strong><\/p>\n


<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n
\n

\u8a79\u68ee\u516c\u53f8\uff08Janssen\uff09\u4e3a\u83b7\u5f97\u6cbb\u7597\u5148\u950b\u751f\u7269\u5236\u836f\u516c\u53f8(Theravance Biopharma)\u7684\u6cbb\u7597\u708e\u75c7\u6027\u80a0\u9053\u75be\u75c5\u7684TD-143\u800c\u51fa\u8d4410\u4ebf\u7f8e\u5143<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/span><\/p>\n

TD-143\u662f\u4e00\u79cd\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u80a0\u5185\u53d7\u9650\u7684\u6cdbJanus\u6fc0\u9176(JAK)\u6291\u5236\u5242\uff0c\u662f\u7528\u4e8e\u6cbb\u7597\u5305\u62ec\u6e83\u75a1\u6027\u7ed3\u80a0\u708e\u548c\u514b\u7f57\u6069\u75c5\u5728\u5185\u7684\u708e\u75c7\u6027\u80a0\u9053\u75be\u75c5\u7684\u5907\u7528\u5316\u5408\u7269\uff0c\u662f\u8a79\u68ee\u516c\u53f8\uff08Janssen\uff09\u548c\u6cbb\u7597\u5148\u950b\u751f\u7269\u5236\u836f\u516c\u53f8(Theravance Biopharma)\u4e4b\u95f4\u7b7e\u7f72\u7684\u534f\u8bae\u7684\u6838\u5fc3\u5185\u5bb9\u3002\u8be5\u516c\u53f8\u5c06\u4ece\u8a79\u68ee\u516c\u53f8\u83b7\u5f971\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u8d39\u7528\uff0c\u4ee5\u53ca\u9ad8\u8fbe9\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/o:p><\/span><\/p>\n

<\/span>
<\/p>\n

<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

Incyte\u516c\u53f8\u548cSyros\u516c\u53f8\u8fbe\u62108.79\u4ebf\u7f8e\u5143\u7684\u5408\u4f5c\u534f\u8bae\uff0c\u5171\u540c\u5f00\u53d1\u9aa8\u9ad3\u589e\u751f\u6027\u80bf\u7624\u57fa\u56e0\u7597\u6cd5<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

<\/span>Incyte\u516c\u53f8\u83b7\u5f97Syros\u516c\u53f8\u7684\u57fa\u56e0\u63a7\u5236\u5e73\u53f0\u7684\u4f7f\u7528\u6743\uff0c\u5171\u540c\u5f00\u53d1\u9488\u5bf9\u9aa8\u9ad3\u589e\u751f\u6027\u80bf\u7624\u7684\u6cbb\u7597\u9776\u70b9\u3002Incyte\u53ef\u9009\u62e9\u83b7\u5f97\u8be5\u5408\u4f5c\u4e2d\u53d1\u73b0\u7684\u6700\u591a7\u4e2a\u9776\u70b9\uff1b\u4f5c\u4e3a\u4ea4\u6362\uff0cSyros\u5c06\u83b7\u5f971250\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e(250\u4e07\u7f8e\u5143\u73b0\u91d1\u548c1,000\u4e07\u7f8e\u5143\u80a1\u7968)\uff0c750\u4e07\u7f8e\u5143\u7684\u7814\u53d1\u8d44\u91d1\uff0c\u53ca\u9ad8\u8fbe8.05\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u8f89\u745e\u4ee58.3\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97Arvinas\u7684PROTAC\u5e73\u53f0\u6388\u6743\uff0c\u56e0\u6b64\u800c\u5f3a\u5316\u5176\u53d1\u73b0\u7ec4\u5408<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/p>\n


<\/span><\/p>\n

Arvinas\u5c06\u5176\u9488\u5bf9\u672a\u62ab\u9732\u9002\u5e94\u75c7\u7684\u86cb\u767d\u964d\u89e3\u9776\u5411\u5d4c\u5408\u7269(PROTAC)\u5e73\u53f0\u6388\u6743\u7ed9\u4e86\u8f89\u745e\u516c\u53f8\u3002\u7528\u4e8e\u4fee\u6539\u5c0f\u5206\u5b50\u6291\u5236\u5242\u7684PROTAC\u662f\u4e00\u79cd\u901a\u8fc7\u5229\u7528\u7ec6\u80de\u7684\u5929\u7136\u548c\u9009\u62e9\u6027\u6cdb\u7d20-\u86cb\u767d\u9176\u4f53\u7cfb\u7edf\uff0c\u964d\u89e3\u81f4\u75c5\u86cb\u767d\u8d28\u4ee5\u53d1\u73b0\u65b0\u7684\u5c0f\u5206\u5b50\u5316\u5408\u7269\u7684\u6280\u672f\u3002\u534f\u8bae\u6240\u6db5\u76d6\u7684\u9002\u5e94\u75c7\u5c1a\u672a\u62ab\u9732\uff0c\u4f46\u8f89\u745e\u5c06\u652f\u4ed88.3\u4ebf\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u3001\u5206\u671f\u4ed8\u6b3e\u4ee5\u53ca\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/o:p><\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\n
\n

Roivant\u516c\u53f8\u4ee56.75\u4ebf\u7f8e\u5143\u83b7\u5f97\u7684Poxel \u516c\u53f8\u7684\u65e8\u5728\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u7684imeglimin\u548c5.338\u4ebf\u7f8e\u5143\u83b7\u5f97\u7684Ligand\u516c\u53f8\u7684LGD-6972\u53d1\u8d77\u6210\u7acb\u65b0\u516c\u53f8\uff1aMetavant Sciences<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/span><\/p>\n

Roivant\u516c\u53f8\u53d6\u5f97\u4e86Poxel\u516c\u53f8\u7684\u65e8\u5728\u6cbb\u7597\u5305\u62ec2\u578b\u7cd6\u5c3f\u75c5\u5728\u5185\u7684\u4ee3\u8c22\u7d0a\u4e71\u7684imeglimin\u53e3\u670d\u836f\u5728\u5305\u62ec\u7f8e\u56fd\u548c\u6b27\u6d32\u5728\u5185\u7684\u3001\u65e5\u672c\u4f4f\u53cb\u5236\u836f\uff08Sumitomo Dainippon\uff09\u76ee\u524d\u5c1a\u4e0d\u62e5\u6709\u6743\u5229\u7684\u6240\u6709\u56fd\u5bb6\u5f00\u53d1\u548c\u63a8\u5e7f\u8be5\u836f\u7684\u6743\u5229\uff0c\u6b64\u9879\u4ea4\u6613\u4ef7\u4e3a 6.75\u4ebf\u7f8e\u5143(\u5305\u62ec5000\u4e07\u7f8e\u5143\u9884\u4ed8\u6b3e\uff0c6\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c2500\u4e07\u7f8e\u5143\u7684\u7814\u53d1\u8d44\u91d1)\u3002Imeglimin\u662f\u4e00\u79cd\u53e3\u670d\u95f4\u63a5AMPK\uff08\u817a\u82f7\u9178\u6d3b\u5316\u86cb\u767d\u6fc0\u9176\uff09\u6fc0\u6d3b\u5242\uff0c\u53ef\u4ee5\u6291\u5236\u809d\u7cd6\u5f02\u751f\uff0c\u7528\u4e8e\u6cbb\u75971\u578b\u7cd6\u5c3f\u75c5\uff0c\u76ee\u524d\u5904\u4e8e\u4e34\u5e8a3\u671f\u3002<\/o:p><\/span><\/p>\n


<\/p>\n

<\/span><\/em><\/strong><\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

Roivant\u516c\u53f8\u53d6\u5f97\u4e86Poxel\u516c\u53f8\u7684\u65e8\u5728\u6cbb\u7597\u5305\u62ec2\u578b\u7cd6\u5c3f\u75c5\u5728\u5185\u7684\u4ee3\u8c22\u7d0a\u4e71\u7684imeglimin\u53e3\u670d\u836f\u5728\u5305\u62ec\u7f8e\u56fd\u548c\u6b27\u6d32\u5728\u5185\u7684\u6240\u6709\u56fd\u5bb6\u5f00\u53d1\u548c\u63a8\u5e7f\u8be5\u836f\u7684\u6743\u5229<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/span><\/em><\/strong>
<\/p>\n

Ligand\u6388\u6743\u8bb8\u53efRoivant\u4f7f\u7528\u5176\u4ea7\u54c1LGD-6972\uff0c\u8fd9\u662f\u4e00\u79cd\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u9ad8\u8840\u7cd6\u7d20\u53d7\u4f53\u62ee\u6297\u5242\uff0c\u76ee\u524d\u6b63\u5728\u8fdb\u884c1\u578b\u548c2\u578b\u7cd6\u5c3f\u75c5\u7684\u4e34\u5e8a\u4e8c\u671f\u5f00\u53d1\uff0c\u8d39\u7528\u9ad8\u8fbe5.338\u4ebf\u7f8e\u5143(\u5305\u62ec2000\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\u548c5.188\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e)\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002LGD-6972\u548cimeglimin\u8fd9\u4e24\u4e2a\u9879\u76ee\u90fd\u5c06\u7531\u65b0\u6210\u7acb\u7684Metavant Sciences\u516c\u53f8\u5f00\u53d1\uff0cMetavant Sciences\u516c\u53f8\u662fRoivant\u7684\u5b50\u516c\u53f8\uff0c\u6210\u7acb\u7684\u76ee\u7684\u65e8\u5728\u63d0\u5347Roivant\u516c\u53f8\u7684\u7cd6\u5c3f\u75c5\u8d44\u4ea7\u3002<\/span><\/o:p><\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\n
\n

\u767e\u5065\uff08Biogen\uff095.9\u4ebf\u7f8e\u5143\u6536\u8d2d\u8f89\u745e\u516c\u53f8\u7684\u6cbb\u7597\u8ba4\u77e5\u969c\u788d\u7684\u65b0\u836fPF-04958242 <\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/span><\/p>\n

<\/span>\u8f89\u745e\u516c\u53f8\u5c06\u5176PF-04958242\u9879\u76ee\u5265\u79bb\u51fa\u552e\u7ed9\u767e\u5065\uff08Biogen\uff09\u516c\u53f8\uff0c\u8fd9\u662f\u4e00\u79cdAMPA\u53d7\u4f53\u589e\u5f3a\u5242\uff0c\u65e8\u5728\u4fc3\u8fdb\u4e0e\u7cbe\u795e\u5206\u88c2\u75c7\u76f8\u5173\u7684\u8ba4\u77e5\u969c\u788d(CIAS)\u7684\u795e\u7ecf\u4f20\u9012\u3002\u767e\u5065\u516c\u53f8\u8ba1\u5212\u57282018\u5e74\u4e0b\u534a\u5e74\u5f00\u59cb\u8fdb\u884c2b\u9636\u6bb5\u7684\u7814\u7a76\u3002\u767e\u5065\u516c\u53f8\u5c06\u652f\u4ed87500\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u8d39\uff0c\u4ee5\u53ca\u9ad8\u8fbe5.15\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\uff0c\u4ee5\u53ca\u8bb8\u53ef\u4f7f\u7528\u8d39\u3002\u8fd9\u7b14\u4ea4\u6613\u5c1a\u672a\u6572\u5b9a\uff0c\u9884\u8ba1\u5c06\u57282018\u5e74\u7b2c\u4e8c\u5b63\u5ea6\u5b8c\u6210\u4ea4\u6613\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

\u8f89\u745e\u516c\u53f8\u5c06\u5176PF-04958242\u9879\u76ee\u5265\u79bb\u51fa\u552e\u7ed9\u767e\u5065\uff08Biogen\uff09\u516c\u53f8\uff0c\u8fd9\u662f\u4e00\u79cdAMPA\u53d7\u4f53\u589e\u5f3a\u5242\uff0c\u65e8\u5728\u4fc3\u8fdb\u4e0e\u7cbe\u795e\u5206\u88c2\u75c7\u76f8\u5173\u7684\u8ba4\u77e5\u969c\u788d(CIAS)\u7684\u795e\u7ecf\u4f20\u9012\u3002<\/strong><\/span><\/p>\n


<\/strong><\/p>\n


<\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u4e9a\u592a\u5730\u533a<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u4eca\u5e74\u7b2c\u4e00\u5b63\u5ea6\uff0c\u4e9a\u592a\u5730\u533a(APAC)\u7684\u4f7f\u7528\u8bb8\u53ef\u4ea4\u6613\u7531\u4e2d\u56fd\u4f01\u4e1a\u4e3b\u5bfc\uff0c\u5171\u62ab\u9732\u534f\u8bae74\u4efd\uff0c\u800c\u65e5\u672c\u4f01\u4e1a\u62ab\u9732\u7684\u4ea4\u6613\u7684\u8d22\u52a1\u4ef7\u503c\u6700\u591a\uff0c\u8d85\u8fc790\u4ebf\u7f8e\u5143\u3002\u65e5\u672c\u7684\u536b\u6750\uff08Eisai\uff09\u548c\u6b66\u7530\uff08Takeda\uff09\u5206\u522b\u4e0e\u9ed8\u514b\u7b7e\u7f72\u4e86\u4ef7\u503c58\u4ebf\u7f8e\u5143\u7684\u80bf\u7624\u5b66\u5408\u4f5c\u534f\u8bae\uff0c\u4e0e\u65b0\u52a0\u5761\u7684Wave Life Sciences\u516c\u53f8\u7b7e\u7f72\u4e86\u6db5\u76d6\u4e86\u53cd\u4e49\u5be1\u6838\u82f7\u9178\u7684\u3001\u4ef7\u503c22.3\u4ebf\u7f8e\u5143\u7684\u534f\u8bae(\u89c1\u56fe4)\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u7f8e\u56fd\u516c\u53f8TG\u7597\u6cd5\uff08TGTherapeutics,\uff09\u83b7\u5f97\u4e86\u6c5f\u82cf\u6052\u745e\u533b\u836f\u7684TG-1701\u4ee5\u53caTG-1702\u7684\u5168\u7403\u72ec\u5bb6\u6388\u6743\uff08\u4e0d\u5305\u62ec\u4e9a\u6d32\u4f46\u5305\u62ec\u65e5\u672c\uff09\uff0cTG-1701\u662f\u5904\u4e8e\u4e34\u5e8a1\u671f\u7684\u4e00\u79cd\u53e3\u670d\u5171\u4ef7\u7ed3\u5408\u7684BTK\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u8054\u5408\u5355\u514b\u9686\u6297\u4f53ublituximab(TG- 1101)\u548cumbralisib( – 1202)\u6cbb\u7597\u8840\u6db2\u6076\u6027\u80bf\u7624\uff1bTG- 1702\u662f\u53e6\u4e00\u4e2a\u5171\u4ef7\u7ed3\u5408\u7684BTK\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5904\u4e8e\u4e34\u5e8a\u524d\u7814\u7a76\u9636\u6bb5\u3002\u6c5f\u82cf\u6052\u745e\u516c\u53f8\u5c06\u83b7\u5f97100\u4e07\u7f8e\u5143\u7684\u80a1\u7968\u9884\u4ed8\u6b3e\uff0c\u5927\u7ea63.5\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u53e6\u4e00\u5bb6\u7f8e\u56fd\u751f\u7269\u6280\u672f\u516c\u53f8Arcutis\u7b7e\u7f72\u4e86\u4e00\u4efd\u6db5\u76d6\u6c5f\u82cf\u6052\u745e\u533b\u836fSHR-0302\u7684\u671f\u6743\u534f\u8bae\uff0cSHR-0302\u53ef\u7528\u4e8e\u6cbb\u7597\u7f8e\u56fd\u3001\u6b27\u6d32\u548c\u65e5\u672c\u7684\u76ae\u80a4\u75be\u75c5\u3002SHR-0302\u662f\u4e00\u79cd\u9009\u62e9\u6027JAK\u6291\u5236\u5242\uff0c\u5728\u4e2d\u56fd\u7528\u4e8e\u6cbb\u7597\u7c7b\u98ce\u6e7f\u5173\u8282\u708e\uff0c\u76ee\u524d\u5904\u4e8e\u4e34\u5e8a2\u671f\u3002\u8fd9\u7b14\u4ea4\u6613\u989d\u9ad8\u8fbe2.33\u4ebf\u7f8e\u5143\uff0c\u5916\u52a0\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u603b\u90e8\u4f4d\u4e8e\u7f8e\u56fd\u5e76\u5728\u4e2d\u56fd\u5f00\u5c55\u4e1a\u52a1\u7684Oncologie\u516c\u53f8\u5c06\u8d1f\u8d23\u5fb7\u56fd\u535a\u6d1b\u6839\u516c\u53f8(Mologen)\u7684lefitolomid\u3002lefitolomid\u662f\u4e00\u79cdTLR9\u6fc0\u52a8\u5242\uff0c\u76ee\u524d\u5904\u4e8e\u7814\u7a761\u671f\uff0c\u4e0eipilimumab\u8054\u7528\uff0c\u6cbb\u7597\u4e2d\u56fd\u3001\u9999\u6e2f\u3001\u6fb3\u95e8\u3001\u53f0\u6e7e\u548c\u65b0\u52a0\u5761\u7684\u80bf\u7624\u60a3\u8005\u3002\u535a\u6d1b\u6839\u516c\u53f8(Mologen)\u6536\u5230500\u4e07\u6b27\u5143\u7684\u9884\u4ed8\u6b3e\uff08\u7ea6\u5408590\u4e07\u7f8e\u5143\uff0c\u5305\u62ec\u73b0\u91d1\u548c\u80a1\u7968\uff09\uff0c\u5e76\u6709\u8d44\u683c\u83b7\u5f971\u4ebf\u6b27\u5143\uff08\u7ea6\u54081.178\u4ebf\u7f8e\u5143)\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u4e2d\u56fd\u516c\u53f8\u5317\u6d77\u5eb7\u6210\uff08CANbridge\uff09\u83b7\u5f97\u4e86\u52a0\u5dde\u5f6a\u9a6c\u751f\u7269\u6280\u672f\u516c\u53f8\uff08Puma Biotechnology\uff09\u7684\u6765\u90a3\u66ff\u5c3c\uff08neratinib\uff09\u4ea7\u54c1\u8bb8\u53ef\uff0c\u6765\u90a3\u66ff\u5c3c\u662f\u4e00\u79cd\u53e3\u670d\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5728\u7f8e\u56fd\u88ab\u6279\u51c6\u7528\u4e8eHER2\u9633\u6027\u4e73\u817a\u764c\uff0c\u5728\u4e2d\u56fd\u5927\u9646\uff0c\u53f0\u6e7e\uff0c\u9999\u6e2f\u548c\u6fb3\u95e8\u4e5f\u83b7\u6279\u4e0a\u5e02\u3002\u4f5c\u4e3a\u56de\u62a5\uff0c\u5f6a\u9a6c\u83b7\u5f97\u4e863000\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\uff0c\u5e76\u6709\u8d44\u683c\u83b7\u5f97\u6700\u9ad8\u8fbe2.55\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u603b\u90e8\u4f4d\u4e8e\u6ce2\u58eb\u987f\u7684NeuroBo\u516c\u53f8\u83b7\u5f97\u4e86\u97e9\u56fd\u4e1c\u963f\u516c\u53f8\uff08Korean Dong-A\uff09\u7684\u5904\u4e8e\u4e34\u5e8a\u4e8c\u671f\u3001\u7528\u4e8e\u6cbb\u7597\u7cd6\u5c3f\u75c5\u795e\u7ecf\u75c5\u53d8\u7684\u5929\u7136\u4ea7\u54c1DA-9801\uff0c\u4ee5\u53ca\u7528\u4e8e\u6cbb\u7597\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u7684\u4e34\u5e8a\u524dDA-9803\u7684\u5168\u7403\u6743\u5229\u3002\u4e1c\u963f\u516c\u53f8\u6536\u5230\u4e86700\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u6b3e\uff08DA-9803\u4e3a500\u4e07\u7f8e\u5143\uff0cDA-9801\u4e3a200\u4e07\u7f8e\u5143\uff09\u300129%\u7684NeuroBo\u80a1\u4efd\uff08DA9803\u4e3a24%\uff0cDA9801\u4e3a5%\uff09\u548c\u9488\u5bf9DA9801\u7684\u3001\u53ef\u80fd\u4e3a1.78\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u3002<\/span><\/p>\n


<\/p>\n

\u7f8e\u56fd\u516c\u53f8Mirati Therapeutics\u6388\u4e8e\u603b\u90e8\u4f4d\u4e8e\u5317\u4eac\u7684\u795e\u5dde\u767e\u6d4e(BeiGene)\u516c\u53f8\u5728\u6fb3\u5927\u5229\u4e9a\u3001\u65b0\u897f\u5170\u548c\u4e9a\u6d32(\u65e5\u672c\u9664\u5916) \u5f00\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u897f\u4ed6\u4f10\u66ff\u5c3c(sitravatinib)\u7684\u72ec\u5bb6\u6743\u5229\u3002\u897f\u4ed6\u4f10\u66ff\u5c3c\u662f\u4e00\u79cd\u7814\u7a76\u578b\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242(RTKs)\uff0c\u5305\u62ecTAM\u53d7\u4f53\u5bb6\u65cf(TYRO3,Axl, MER)\uff0c\u5206\u88c2\u5bb6\u65cf\u53d7\u4f53(VEGFR2\uff0cKIT)\u548cRET\u3002Mirati\u83b7\u5f971000\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u8d39\uff0c\u5e76\u6709\u8d44\u683c\u83b7\u5f97\u9ad8\u8fbe1.23\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/p>\n

\u603b\u90e8\u4f4d\u4e8e\u4e9a\u592a\u5730\u533a\u7684\u516c\u53f8<\/span>2018<\/span>\u5e74\u7b2c\u4e00\u5b63\u5ea6\u516c\u5e03\u7684\u8bb8\u53ef\u534f\u8bae<\/span><\/strong><\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

\u56fe4\uff1a2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u67d0\u4e9b\u603b\u90e8\u4f4d\u4e8e\u4e9a\u592a\u5730\u533a\u7684\u516c\u53f8\u62ab\u9732\u7684\u4ea4\u6613\u603b\u989d\u548c\u4ea4\u6613\u89c4\u6a21(\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/em><\/p>\n


<\/p>\n

\u9ad8\u4ea7\u7684\u4ea4\u6613\u5927\u5e84\u5bb6<\/span><\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u7b2c\u4e00\u5b63\u5ea6\u6700\u5f15\u4eba\u6ce8\u76ee\u7684\u4ea4\u6613\u6570\u636e\u90fd\u662f\u6765\u81ea\u4e8e\u901a\u5e38\u7684\u5927\u578b\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5305\u62ec\u8f89\u745e(Pfizer)\u3001\u963f\u65af\u5229\u5eb7(AstraZeneca)\u548c\u9ed8\u514b(Merck)\uff0c\u4e3b\u8981\u7684\u6cbb\u7597\u91cd\u70b9\u662f\u764c\u75c7\u3002<\/span>
<\/p>\n

\n
\n
\n
<\/section>\n
\n

\u8f89\u745e<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u8f89\u745e\u83b7\u8bb8\u4f7f\u7528Adapsyn\u516c\u53f8\u7684\u751f\u7269\u4fe1\u606f\u5b66\u5e73\u53f0\uff0c\u4e13\u6ce8\u4e8e\u5f00\u53d1\u73af\u5883\u5fae\u751f\u7269\u7fa4\u843d\uff0c\u65b9\u6cd5\u662f\u9009\u62e9\u6027\u5730\u4ece\u8f89\u745e\u7684\u5fae\u751f\u7269\u83cc\u682a\u4e2d\u5206\u79bb\u65b0\u5236\u5242\u3002\u8be5\u5e73\u53f0\u5c06\u57fa\u56e0\u7ec4\u548c\u4ee3\u8c22\u6570\u636e\u4e0e\u4eba\u5de5\u667a\u80fd\u548c\u673a\u5668\u5b66\u4e60\u6280\u672f\u76f8\u7ed3\u5408\u3002\u5982\u679c\u8f89\u745e\u5728\u5408\u4f5c\u534f\u8bae\u4e0b\u5f00\u53d1\u51fa\u4efb\u4f55\u5316\u5408\u7269\uff0cAdapsyn\u516c\u53f8\u5c06\u83b7\u5f97\u9ad8\u8fbe1.62\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002\u4e0e\u6b64\u540c\u65f6\uff0c\u5047\u5982Adapsyn\u5229\u7528\u8f89\u745e\u7684\u5fae\u751f\u7269\u83cc\u7fa4\u5f00\u53d1\u51fa\u4efb\u4f55\u5316\u5408\u7269\uff0c\u8f89\u745e\u5c06\u83b7\u5f97\u672a\u62ab\u9732\u91d1\u989d\u7684\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\uff0cKite Pharma\u548cPfizer\u516c\u53f8\u540c\u610f\u5bf9\u5747\u5904\u4e8e1\/2\u671f\u7814\u7a76\u7684Kite\u516c\u53f8\u7684axicabtageneciloleuce\u548c\u8f89\u745e\u516c\u53f8\u7684utomilumab \u8fdb\u884c\u8bc4\u4f30\uff0c\u524d\u8005\u662f\u4e00\u79cd\u5d4c\u5408\u6297\u539f\u53d7\u4f53T (CAR-T)\u7ec6\u80de\u7597\u6cd5\uff0c\u540e\u8005\u4e00\u79cd\u5b8c\u5168\u4eba\u6027\u5316\u76844-1BB\u6fc0\u52a8\u5242\u5355\u514b\u9686\u6297\u4f53\uff0c\u4e24\u8005\u5747\u7528\u4e8e\u6cbb\u7597\u96be\u6cbb\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u3002\u53cc\u65b9\u5747\u4e3a\u900f\u9732\u534f\u8bae\u7684\u8d22\u52a1\u6761\u6b3e\u3002<\/span><\/p>\n


<\/p>\n

\u8f89\u745e\u516c\u53f8\u8d2d\u5f97\u4e86Imcyse\u7684imotope\u9009\u62e9\u6743\uff0cimotope\u662f\u4e00\u79cd\u7279\u6b8a\u7684\u6539\u826f\u80bd\uff0c\u4ee5\u8bf1\u5bfc\u7ec6\u80de\u6eb6\u89e3\u6027T\u7ec6\u80de\uff0c\u8fd9\u79cdT\u7ec6\u80de\u80fd\u591f\u4e3b\u52a8\u800c\u7279\u5f02\u6027\u5730\u6740\u6b7b\u4e0e\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u76f8\u5173\u7684\u514d\u75ab\u7ec6\u80de\uff0c\u5305\u62ec\u7c7b\u98ce\u6e7f\u5173\u8282\u708e\u548c\u591a\u53d1\u6027\u786c\u5316\u75c7\u7b49\u75be\u75c5\u3002\u8be5\u516c\u53f8\u8fd8\u83b7\u5f97\u4e86Imcyse\u516c\u53f8\u7684\u53e6\u4e00\u79cd\u9488\u5bf9\u591a\u53d1\u6027\u786c\u5316\u75c7\u836f\u7269imotope\u7684\u6743\u5229\uff0c\u4ee5\u4e86\u89e3\u5176\u4f5c\u7528\u673a\u5236\u3002\u4f5c\u4e3a\u4ea4\u6362\uff0c\u8f89\u745e\u5c06\u4e3aImcyse\u516c\u53f8\u63d0\u4f9b\u7814\u53d1\u8d39\u7528\u3002<\/span><\/p>\n


<\/p>\n

\u603b\u90e8\u4f4d\u4e8e\u4e2d\u56fd\u7684\u82cf\u5dde\u5f00\u62d3\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08Suzhou KintorPharmaceuticals\uff09\u83b7\u5f97\u8f89\u745e\u516c\u53f8(Pfizer)\u7684ascrinvacumab\u6388\u6743\uff0cascrinvacumab\u662f\u4e00\u79cd\u5904\u4e8e\u4e34\u5e8a2\u671f\u7684\u9488\u5bf9\u6d3b\u5316\u7d20\u53d7\u4f53\u6837\u6fc0\u9176-1\uff08Activin receptor-like kinase-1,ALK-1\uff09\u9776\u70b9\u7684\u6297\u8840\u7ba1\u751f\u6210\u7684\u5168\u4eba\u6e90IgG2 mAb\uff0c\u7528\u4e8e\u6cbb\u7597\u809d\u7ec6\u80de\u764c\u3002\u6b64\u4ea4\u6613\u7684\u5177\u4f53\u91d1\u989d\u4e0d\u8be6\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u660e\u8fea\u59c6\u5c3c\u7597\u6cd5\u516c\u53f8\uff08MindImmuneTherapeutics\uff09\u548c\u8f89\u745e\u516c\u53f8\u540c\u610f\u4f7f\u7528\u660e\u8fea\u59c6\u5c3c\u7684\u514d\u75ab\u7ec6\u80de\u5e73\u53f0\uff0c\u5bf9\u4e00\u79cd\u4ee5\u524d\u672a\u88ab\u786e\u8ba4\u7684\u5916\u5468\u514d\u75ab\u7ec6\u80de\u5728\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u7d0a\u4e71\u4e2d\u7684\u4f5c\u7528\u8fdb\u884c\u7814\u7a76\u3002\u8f89\u745e\u5c06\u901a\u8fc7\u5176\u65b0\u5174\u6280\u672f\u57fa\u91d1\u6295\u8d44\u4e00\u7b14\u91d1\u989d\u4e0d\u8be6\u7684\u8d44\u91d1\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
<\/section>\n
\n

\u9ed8\u514b\u516c\u53f8<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u5982\u524d\u6240\u8ff0\uff0c\u9ed8\u514b(Merck)\u4e0e\u536b\u6750(Eisai)\u7b7e\u7f72\u4e86\u672c\u5b63\u5ea6\u6d89\u53ca\u5f6d\u5e03\u7f57\u7ea6\u5355\u6297\uff08pembrolizumab\uff09\u7684\u6700\u5927\u989d\u4ea4\u6613\u534f\u8bae\u3002\u6b64\u5916\uff0cIO\u751f\u7269\u6280\u672f\u516c\u53f8\uff08IO Biotech\uff09\u8fd8\u4e0e\u9ed8\u514b\u516c\u53f8\u5408\u4f5c\uff0c\u5728\u7b2c1\/2\u7684\u7814\u7a76\u4e2d\u8bc4\u4f30\u8be5\u836f\u7269\u4e0eIO\u751f\u7269\u6280\u672f\u516c\u53f8\u7684IO-102(\u4e00\u79cdIDO\u884d\u751f\u514d\u75ab\u8c03\u8282\u7597\u6cd5)\u8054\u7528\uff0c\u6709\u53ef\u80fd\u4f5c\u4e3a\u8f6c\u79fb\u6027\u975e\u5c0f\u7ec6\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u7684\u4e00\u7ebf\u6cbb\u7597\u65b9\u6848\u7684\u6548\u679c\u3002IO\u751f\u7269\u6280\u672f\u516c\u53f8\u5c06\u8d5e\u52a9\u8fd9\u9879\u8bd5\u9a8c\uff0c\u4e24\u5bb6\u516c\u53f8\u5c06\u5206\u4eab\u7814\u7a76\u7684\u6570\u636e\u3002<\/span><\/p>\n


<\/p>\n

PharmAbcine\u516c\u53f8\u8fd8\u5c06\u5c31\u6d3e\u59c6\u5355\u6297\uff08pembrolizumab\uff09\u8054\u5408\u9ed8\u514b\u516c\u53f8\u7684\u6297VEGFR2\uff08KDR \/ flk-1\uff09\u5355\u514b\u9686\u6297\u4f53TTAC-0001\u5bf9\u590d\u53d1\u6027\u591a\u5f62\u6027\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u548c\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\u8fdb\u884c1 \/ 2\u671f\u7814\u7a76\u3002\u53cc\u65b9\u672a\u62a5\u544a\u8d22\u52a1\u7ec6\u8282\u3002<\/span><\/p>\n


<\/p>\n

\u53e6\u4e00\u5bb6\u540d\u4e3aImmutep\u7684\u516c\u53f8\u5c06\u5bf9\u5176eftilagimod-\u03b1\u4e0e\u5904\u4e8e\u4e34\u5e8a2\u671f\u7684pembrolizumab\u7684\u7ec4\u5408\u7597\u6cd5\u5bf9\u975e\u5c0f\u7ec6\u80de\u80ba\u764c(NSCLC)\u3001\u5934\u9888\u764c\u6216\u5375\u5de2\u764c\u7684\u7597\u6548\u8fdb\u884c\u8bc4\u4f30\uff0ceftilagimod-\u03b1\u884d\u751f\u4e8eLAG-3Ig\u878d\u5408\u86cb\u767d(CD223)\u3002\u8d22\u52a1\u7ec6\u8282\u672a\u4e88\u62ab\u9732\u3002<\/span><\/p>\n

\u539f\u6838\u751f\u7269\u516c\u53f8\uff08Prokaryotics\uff09\u53d6\u5f97\u4e86\u9ed8\u514b\u516c\u53f8\u7684\u65e9\u671f\u4e34\u5e8a\u524d\u6297\u751f\u7d20\u7684\u6743\u5229\uff0c\u8be5\u6297\u751f\u7d20\u9488\u5bf9\u7684\u662f\u591a\u91cd\u8010\u836f\u83cc\u611f\u67d3\u4e2d\u7684\u9769\u5170\u6c0f\u9634\u6027\u548c\u9769\u5170\u6c0f\u9633\u6027\u7ec6\u83cc\u5305\u819c\u9176\uff0c\u534f\u8bae\u91d1\u989d\u4e0d\u8be6(\u89c1\u56fe5)\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
<\/section>\n
\n

\u963f\u65af\u5229\u5eb7<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u963f\u65af\u5229\u5eb7\uff08AZ\uff09\u548c\u5df4\u4f10\u5229\u4e9a\u5317\u6b27\uff08Bavarian Nordic\uff09\u8054\u624b\u5bf9\u5df4\u4f10\u5229\u4e9a\u7684CV-301\uff08\u4e00\u79cd\u57fa\u4e8e\u75d8\u75c5\u6bd2\u7684\u521d\u514d\/\u52a0\u5f3a\u75ab\u82d7\uff09\u76841\/ 2\u671f\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86\u8bc4\u4f30\uff0c\u8be5\u75ab\u82d7\u91c7\u7528\u4e86\u4e00\u79cd\u6539\u826f\u7248\u725b\u75d8\u4f5c\u4e3a\u521d\u59cb\u5242\u91cf\uff0c\u968f\u540e\u8fdb\u884c\u4e86\u591a\u6b21\u9e21\u75d8\u52a0\u5f3a\uff0c\u548c\u963f\u65af\u5229\u5eb7\u7684PD-L1\u68c0\u67e5\u70b9\u6291\u5236\u5242durvalumab\u7ec4\u5408\uff0c\u7528\u4e8e\u8f6c\u79fb\u6027\u7ed3\u76f4\u80a0\u764c\u548c\u80f0\u817a\u764c\u7684\u6f5c\u5728\u6cbb\u7597\u65b9\u6848\u3002\u53cc\u65b9\u6ca1\u6709\u62ab\u9732\u8d22\u52a1\u7ec6\u8282\u3002<\/span><\/p>\n


<\/p>\n

\u963f\u65af\u5229\u5eb7\u8fd8\u51b3\u5b9a\u5728\u4e00\u98791b\u671f\u7814\u7a76\u4e2d\u5bf9durvalumab\u8054\u7528Syndax Pharmaceuticals\u516c\u53f8\u7684SNDX-6352\uff08\u4e00\u79cd\u6291\u5236\u96c6\u843d\u523a\u6fc0\u56e0\u5b501\u53d7\u4f53\uff08CSF1R\uff09\u7684\u5355\u514b\u9686\u6297\u4f53\uff09\u6cbb\u7597\u5b9e\u4f53\u7624\u60a3\u8005\u8fdb\u884c\u8bc4\u4f30\uff0c\u4f46\u672a\u900f\u9732\u91d1\u989d\u3002<\/span><\/p>\n


<\/p>\n

\u4e1c\u963fST\u548c\u963f\u65af\u5229\u5eb7\u5408\u4f5c\uff0c\u9488\u5bf9\u4e09\u4e2a\u672a\u62ab\u9732\u7684\u764c\u75c7\u6f5c\u5728\u6cbb\u7597\u9776\u70b9\uff0c\u5f00\u53d1\u5019\u9009\u836f\u7269\u3002\u8d22\u52a1\u6761\u6b3e\u5c1a\u672a\u900f\u9732\u3002<\/span><\/p>\n


<\/p>\n

\u7f8e\u56fd\u67e5\u5c14\u65af\u6cb3\u5b9e\u9a8c\u5ba4\u516c\u53f8\u53d6\u5f97\u4e86\u963f\u65af\u5229\u5eb7\u516c\u53f8\u7684\u9ad8\u901a\u91cf\u7b5b\u9009(HTS)\u6280\u672f\u548c\u5316\u5408\u7269\u7ba1\u7406\u57fa\u7840\u8bbe\u65bd\uff0c\u8fd9\u4e9b\u57fa\u7840\u8bbe\u65bd\u5c06\u7eb3\u5165\u5176\u670d\u52a1\uff0c\u5177\u4f53\u4ea4\u6613\u6570\u989d\u4e0d\u8be6\u3002\u6b64\u5916\uff0c\u67e5\u5c14\u65af\u6cb3\u5b9e\u9a8c\u5ba4\u516c\u53f8\u5c06\u4f7f\u7528\u963f\u65af\u5229\u5eb7\u7684\u5148\u5bfc\u5316\u5408\u7269\u53d1\u73b0\u4e2d\u5fc3\u6765\u7ba1\u7406\u5176\u5316\u5408\u7269\u7684\u6536\u96c6\u548c\u5b9e\u65bd\u9ad8\u901a\u91cf\u7b5b\u9009(HTS)\u6280\u672f\u3002<\/span><\/p>\n


<\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

\u56fe5\uff1a\u9ed8\u514b\u516c\u53f8 2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u4ea4\u6613\u7cbe\u9009\u3002(\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/em><\/p>\n


<\/span><\/p>\n

<\/span><\/p>\n

\u5206\u671f\u4ed8\u6b3e<\/span><\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u672c\u5b63\u5ea6\u6700\u5927\u989d\u5206\u671f\u4ed8\u6b3e\u7684\u63a5\u53d7\u65b9\u5305\u62ecChemoCentryx\u3001Aicuris\u3001Five Prime\u548cExelixis(\u89c1\u88681)\u3002<\/span>
<\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

\u88681\uff1a2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\u6700\u5927\u989d\u5206\u671f\u4ed8\u6b3e\u3002(\u6765\u6e90:Cortellis Competitive Intelligence, Clarivate Analytics)<\/span><\/em><\/p>\n


<\/p>\n

\u65e5\u672c\u57281\u6708\u4efd\u6279\u51c6elobixibat\u6cbb\u7597\u6162\u6027\u4fbf\u79d8\uff0c\u6b64\u9879\u6279\u51c6\u89e6\u53d1\u4e86EA Pharma\u516c\u53f8\u548cHealthCare Royalty Partners (HCR)\u516c\u53f8\u5bf9Albireo Pharma\u516c\u53f8\u7684\u5927\u7ea65500\u4e07\u7f8e\u5143\u7684\u7279\u8bb8\u4ed8\u6b3e\uff0c\u5176\u4e2dEA Pharma\u4e3a1000\u4e07\u7f8e\u5143\uff0cHCR\u4e3a4500\u4e07\u7f8e\u5143\u3002\u5728\u65e5\u672c\u6279\u51c6\u8be5\u836f\u7269\u7684\u4e00\u4e2a\u6708\u524d\uff0cAlbireo\u548cHCR\u7b7e\u7f72\u4e86\u4e00\u9879\u6d89\u53caEA Pharma\u8bb8\u53ef\u7684\u7279\u8bb8\u6743\u6536\u8d2d\u4ea4\u6613\uff0c\u91d1\u989d\u8d85\u8fc76000\u4e07\u7f8e\u5143\u30022012\u5e744\u6708\uff0cEA Pharma\u83b7\u5f97\u4e86\u5728\u4e9a\u6d32\u5e02\u573a\u5f00\u53d1\u548c\u5546\u4e1a\u5316elobixibat\u7684\u6743\u5229\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u53d7\u7406\u5ba1\u67e5\u5b64\u513f\u836favacopan (\u4e00\u79cd\u53e3\u670dC5a\u53d7\u4f53\u62ee\u6297\u5242)\u7684\u6761\u4ef6\u6027\u4e0a\u5e02\u6388\u6743(CMA)\u7533\u8bf7\uff0c\u6b64\u836f\u7528\u4e8e\u6cbb\u7597\u6297\u4e2d\u6027\u7c92\u7ec6\u80de\u80de\u6d46\u81ea\u4f53\u6297\u4f53\u76f8\u5173\u6027\u8840\u7ba1\u708e(ANCA-associated vasculitis)\u3002\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40(EMA)\u7684\u6b64\u9879\u5ba1\u67e5\u89e6\u53d1\u4e86ChemoCentryx\u7684\u5408\u4f5c\u4f19\u4f34Vifor Fresenius MedicalCare Renal Pharma\u516c\u53f8\u5bf9\u51765000\u4e07\u7f8e\u5143\u7684\u4ed8\u6b3e\u30022016\u5e745\u6708\uff0cVifor\u4ee5\u8d85\u8fc76.65\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97\u4e86\u6b64\u9879\u76ee\u8fdb\u5165\u9664\u7f8e\u56fd\u548c\u4e2d\u56fd\u4ee5\u5916\u7684\u6b27\u6d32\u548c\u5176\u5b83\u5e02\u573a\u7684\u6743\u5229\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5728\u6b27\u6d32\u6279\u51c6letermovir\u4e0a\u5e02\u540e\uff0c\u9ed8\u514b\u516c\u53f8\u5411AiCuris\u516c\u53f8\u652f\u4ed8\u4e863000\u4e07\u6b27\u5143\uff08\u7ea6\u54083530\u4e07\u7f8e\u5143\uff09\uff0cletermovir\u662f\u4e00\u79cd\u975e\u6838\u82f7\u9178\u672b\u7aef\u9176\u6291\u5236\u5242\uff0c\u7528\u4e8e\u9884\u9632\u5de8\u7ec6\u80de\u75c5\u6bd2\uff08CMV\uff09\u611f\u67d3\u30022012\u5e7410\u6708\uff0c\u9ed8\u514b\u516c\u53f8\u4ee5\u8d85\u8fc75.74\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\uff0c\u83b7\u5f97\u4e86AiCuris\u516c\u53f8\u7684\u53e6\u5916\u51e0\u4e2a\u5de8\u7ec6\u80de\u75c5\u6bd2\u5019\u9009\u836f\u7684\u5168\u7403\u4ee3\u7406\u6743\u3002<\/span><\/p>\n


<\/span><\/p>\n

Five Prime\u516c\u53f8\u7684 cabirzumaliab\u4e0e\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d(BMS)\u7684nivolumab\u8054\u5408\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u80f0\u817a\u764c\u7684\u7b2c2\u671f\u7814\u7a76\u542f\u52a8\u540e\uff0c\u89e6\u53d1\u4e86\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u5bf9Five Prime\u76842500\u4e07\u7f8e\u5143\u7684\u4ed8\u6b3e\u3002\u53cc\u65b9\u662f\u57282015\u5e7410\u6708\u7b7e\u7f72\u7684\u534f\u8bae\uff0c\u4ef7\u503c17.4\u4ebf\u7f8e\u5143\u3002<\/span><\/p>\n


<\/span><\/p>\n

Exelixis\u516c\u53f8\u5728\u5411\u65e5\u672c\u63d0\u4ea4\u975e\u753e\u4f53\u76d0\u76ae\u8d28\u6fc0\u7d20\u53d7\u4f53\uff08MR\uff09\u62ee\u6297\u5242esaxerenone\u7684\u6279\u51c6\u7533\u8bf7\u540e\uff0c\u4fbf\u4ece\u7b2c\u4e00\u5236\u836f\u4e09\u5171\u516c\u53f8\uff08Daiichi Sankyo\uff09\u5f97\u5230\u4e862000\u4e07\u7f8e\u5143\u7684\u4ed8\u6b3e\u3002\u7b2c\u4e00\u5236\u836f\u4e09\u5171\u516c\u53f8\u662f\u57282006\u5e743\u6708\u4ee5\u5927\u7ea61.8\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u5f97\u5230Exelixis\u516c\u53f8\u7684MR\u62ee\u6297\u5242\u6388\u6743\u8bb8\u53ef\u7684\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u6b27\u6d32\u6279\u51c6darvadstrocel\u4e0a\u5e02\u540e\uff0c\u6b66\u7530\u516c\u53f8\u5411TiGenix\u516c\u53f8\u652f\u4ed8\u4e861500\u4e07\u6b27\u5143(\u7ea6\u54081770\u4e07\u7f8e\u5143)\uff0cdarvadstrocel \u662f\u4e00\u79cd\u5f02\u57fa\u56e0\u5e72\u7ec6\u80de\u7597\u6cd5\uff0c\u7528\u4e8e\u6cbb\u7597\u514b\u7f57\u6069\u75c5\u4e2d\u7684\u590d\u6742\u809b\u5468\u7618\u7ba1\u30022016\u5e747\u6708\uff0c\u6b66\u7530\u83b7\u5f97\u8be5\u836f\u9664\u7f8e\u56fd\u4ee5\u5916\u5730\u533a\u7684\u7279\u8bb8\u4f7f\u7528\u6743\uff0c\u4ea4\u6613\u4ef7\u7ea6\u4e3a4.17\u4ebf\u7f8e\u5143\u3002\u6700\u8fd1, \u4e5f\u5c31\u662f\u4eca\u5e74\u4e00\u6708\uff0c\u8be5\u65e5\u672c\u516c\u53f8\uff08\u6b66\u7530\u516c\u53f8\uff09\u5ba3\u5e03\u6253\u7b97\u4ee55.2\u4ebf\u6b27\u5143\uff08\u7ea6\u54086.12\u4ebf\u7f8e\u5143\uff09\u7684\u4ef7\u683c\u6536\u8d2dTiGenix\u516c\u53f8\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5728\u542f\u52a8BI-1467335\u76842a\u671f\u7814\u7a76\u540e\uff0cPharmaxis\u6536\u5230\u4e86\u6765\u81ea\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u516c\u53f8(BI)\u76841000\u4e07\u6b27\u5143(\u7ea6\u54081180\u4e07\u7f8e\u5143)\u4ed8\u6b3e\uff0cBI-1467335\u662f\u4e00\u79cd\u6c28\u57fa\u8132\u654f\u611f\u7684\u80fa\u6c27\u5316\u7269\uff08SSAO\uff09\/\u8840\u7ba1\u7c98\u9644\u86cb\u767d-1\uff08VAP-1\uff09\u6291\u5236\u5242\uff0c\u7528\u4e8e\u6cbb\u7597\u7cd6\u5c3f\u75c5\u89c6\u7f51\u819c\u75c5\u53d8\u30022015\u5e74\uff0cBI\u516c\u53f8\u4ee5\u5927\u7ea66\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97\u4e86Pharmaxis\u516c\u53f8\u7684SSAO\/ vap1\u5316\u5408\u7269\u7684\u7279\u8bb8\u4f7f\u7528\u6743\u3002<\/span><\/p>\n


<\/span><\/p>\n

GLPG-2851\u662f\u7b2c\u4e00\u4ee3\u5177\u6709\u65e9\u671f\u7ed3\u5408\u529f\u80fd\u7684CFTR\u6821\u6b63\u5242\uff0c\u73b0\u5df2\u5bf9\u56ca\u6027\u7ea4\u7ef4\u5316(CF)\u60a3\u8005\u8fdb\u884c\u4e34\u5e8a1\u671f\u8bd5\u9a8c\uff0c\u8fd9\u4fbf\u89e6\u53d1\u4e86AbbVie\u516c\u53f8\u5411Galapagos\u516c\u53f81000\u4e07\u7f8e\u5143\u4ed8\u6b3e\u30022013\u5e749\u6708\uff0c\u4e24\u5bb6\u516c\u53f8\u7b7e\u7f72\u4e86\u4e00\u9879\u534f\u8bae\uff0c\u534f\u8bae\u5305\u542b\u82e5\u5e72\u4e0d\u540c\u7684CF\u7597\u6cd5\uff0c\u534f\u8bae\u91d1\u989d\u4f30\u8ba1\u4f1a\u8fbe6.625\u4ebf\u7f8e\u5143\u3002<\/span><\/p>\n


<\/span><\/p>\n

Akebia Therapeutics\u516c\u53f8\u542f\u52a8vadadustat\u76843\u671f\u7814\u7a76\u540e\uff0c\u4fbf\u4ece\u4e09\u83f1\u7530\u8fb9\u516c\u53f8(Mitsubishi Tanabe)\u83b7\u5f97\u4e861000\u4e07\u7f8e\u5143\u4ed8\u6b3e\uff0c vadadustat\u662f\u4e00\u79cd\u4f4e\u6c27\u8bf1\u5bfc\u56e0\u5b50\u812f\u6c28\u9170\u7f9f\u5316\u9176\u6291\u5236\u5242\uff0c\u7528\u4e8e\u6cbb\u7597\u65e5\u672c\u975e\u900f\u6790\u4f9d\u8d56\u548c\u900f\u6790\u4f9d\u8d56\u7684\u6162\u6027\u80be\u75c5\u60a3\u8005\u7684\u8d2b\u8840\u75c7\u30022015\u5e7412\u6708\uff0c\u4e09\u83f1\u7530\u8fb9\u516c\u53f8\u51ed\u501f\u8d85\u8fc73.75\u4ebf\u7f8e\u5143\u7684\u5408\u4f5c\u534f\u8bae\u83b7\u5f97\u4e86Akebia\u516c\u53f8\u7684vadadustat\u5728\u4e9a\u6d32\u5e02\u573a\u7684\u7279\u8bb8\u4f7f\u7528\u6743\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5728\u7f8e\u56fd\u6279\u51c6\u4e09\u6c27\u5316\u4e8c\u7837\u8054\u5408\u7ef4\u7532\u9178\u6cbb\u7597\u65b0\u8bca\u65ad\u7684\u4f4e\u98ce\u9669\u6025\u6027\u65e9\u5e7c\u7c92\u7ec6\u80de\u767d\u8840\u75c5(APL)\u540e\uff0cTeva\u516c\u53f8\u5411CTI\u751f\u7269\u5236\u836f\u516c\u53f8\u652f\u4ed8\u4e861000\u4e07\u7f8e\u5143\u30022002\u5e743\u6708\uff0cTeva\u516c\u53f8\u83b7\u5f97\u4e86CTI\u9879\u76ee\u7684\u5546\u4e1a\u5316\u6743\u5229\u3002\u540e\u6765\u57282005\u5e74\uff0c\u745f\u6cd5\u9686\u516c\u53f8\uff08Cephalon\uff09\u4ee5\u9ad8\u8fbe1.7\u4ebf\u7f8e\u5143\u7684\u4ef7\u683c\uff0c\u8d2d\u5f97\u4e09\u6c27\u5316\u4e8c\u7837\u3002\u7136\u800c\uff0c2011\u5e74Teva\u516c\u53f8\u4ee568\u4ebf\u7f8e\u5143\u6536\u8d2dCephalon\u4e4b\u540e\uff0c\u8be5\u836f\u4fbf\u843d\u5165Teva\u624b\u4e2d\u3002<\/span><\/p>\n


<\/p>\n


<\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

\u5728\u7f8e\u56fd\u6279\u51c6\u4e09\u6c27\u5316\u4e8c\u7837\u8054\u5408\u7ef4\u7532\u9178\u6cbb\u7597\u65b0\u8bca\u65ad\u7684\u4f4e\u98ce\u9669\u6025\u6027\u65e9\u5e7c\u7c92\u7ec6\u80de\u767d\u8840\u75c5(APL)\u540e\uff0cTeva\u516c\u53f8\u5411CTI\u751f\u7269\u5236\u836f\u516c\u53f8\u652f\u4ed8\u4e861000\u4e07\u7f8e\u5143\u3002<\/strong><\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n


<\/p>\n

\u9009\u62e9\u548c\u7ec8\u6b62<\/span><\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u672c\u5b63\u5ea6\uff0c\u8d5b\u8bfa\u83f2(Sanofi)<\/span>\u548cAllergan<\/span>\u7b49\u5927\u578b\u5236\u836f\u516c\u53f8\u5c65\u884c\u4e86\u591a\u9879\u9009\u62e9\uff0c\u540c\u65f6\u4e5f\u89c1\u8bc1\u4e86\u591a\u4e2a\u91cd\u8981\u7684\u5927\u989d\u4ea4\u6613\u7684\u7ec8\u6b62\u3002<\/span><\/p>\n


<\/p>\n

\u4eca\u5e742\u6708\uff0c\u8d5b\u8bfa\u83f2\u516c\u53f8\u9009\u62e9\u8bb8\u53ef\u4e24\u4e2a\u4ee5\u4e0a\u7684Ablynx\u516c\u53f8\u7684\u591a\u7279\u5f02\u6027\u7eb3\u7c73\u6297\u4f53\u4ea7\u54c1\u5019\u9009\u836f\uff0c\u5373\u6765\u6e90\u4e8e\u9a86\u9a7c\u79d1\u7684\u4ec5\u542b\u91cd\u94fe\u7684\u6297\u4f53\uff0c\u53ef\u80fd\u7528\u4e8e\u514d\u75ab\u4ecb\u5bfc\u7684\u708e\u6027\u75be\u75c5\u7684\u9009\u62e9\u6027\u9776\u70b9\uff0c\u8bb8\u53ef\u4ea4\u6613\u4ef7\u4e3a1300\u4e07\u6b27\u5143(\u7ea61620\u4e07\u7f8e\u5143)\u30022017\u5e747\u6708\uff0c\u53cc\u65b9\u7b7e\u7f72\u4e86\u6db5\u76d68\u4e2a\u7eb3\u7c73\u6297\u4f53\u7684\u534f\u8bae\uff0c\u603b\u91d1\u989d\u8fbe24.3\u4ebf\u6b27\u5143\uff08\u7ea6\u540828.2\u4ebf\u7f8e\u5143\uff09\uff0c\u53e6\u52a0\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002\u6700\u8fd1\uff0c\u5373\u4eca\u5e741\u6708\uff0c\u8d5b\u8bfa\u83f2\u516c\u53f8\u5ba3\u5e03\u8ba1\u5212\u4ee539\u4ebf\u6b27\u5143(\u7ea646\u4ebf\u7f8e\u5143)\u7684\u4ef7\u683c\u6536\u8d2dAblynx\u516c\u53f8\u3002<\/span><\/p>\n


<\/p>\n

\u827e\u5c14\u5efa\u516c\u53f8\uff08Allergan\uff09\u884c\u4f7f\u4e86\u7b2c\u4e09\u4e2a\u9009\u62e9\u6743\uff0c\u4ee5\u83b7\u5f97Molecular Partners\u516c\u53f8\u7684\u3001\u9488\u5bf9\u773c\u79d1\u75be\u75c5\u9009\u5b9a\u9776\u70b9\u7684\u805a\u4e59\u4e8c\u9187\u951a\u86cb\u767d\u91cd\u590d\u86cb\u767d(DARPin)\u5019\u9009\u836f\u7684\u6743\u5229\u3002\u6b64\u524d\uff0c\u57282017\u5e7412\u6708\uff0c\u827e\u5c14\u5efa\u5df2\u7ecf\u884c\u4f7f\u4e86\u5bf9\u5176\u5b83\u4e24\u4e2aDARPin\u5316\u5408\u7269\u7684\u9009\u62e9\u6743\u3002\u6700\u521d\uff0c\u53cc\u65b9\u662f\u57282011\u5e745\u6708\u7b7e\u7f72\u4e86\u7b2c\u4e00\u4efd\u534f\u8bae\uff0c\u6d89\u53ca\u5230Molecular\u516c\u53f8\u7684abicipar pegol\uff0c\u8fd9\u4e5f\u662f\u4e00\u79cdDARPin\u5316\u5408\u7269\uff0c\u662f\u5904\u4e8e\u4e34\u5e8a3\u671f\u7684\u4e13\u95e8\u5b9a\u5411\u5bf9\u6297VEGF-A\uff0c\u7528\u4e8e\u6cbb\u7597\u6e7f\u6027\u8001\u5e74\u6027\u9ec4\u6591\u53d8\u6027\u7684\u836f\u7269\uff0c\u8be5\u534f\u8bae\u5546\u5b9a\u7684\u9884\u4ed8\u8d39\u7528\u4e3a4500\u4e07\u7f8e\u5143\u548c\u9ad8\u8fbe3.75\u4ebf\u7f8e\u5143\u7684\u5206\u671f\u4ed8\u6b3e\u53ca\u7279\u8bb8\u4f7f\u7528\u8d39\u30022012\u5e74\u665a\u4e9b\u65f6\u5019\uff0c\u53cc\u65b9\u5206\u522b\u7b7e\u7f72\u4e86\u4e24\u4efd\u534f\u8bae\uff0c\u5176\u4e2d\u5305\u62ecMP-0260\u7684\u6743\u5229\uff08MP-0260\u662f\u4e00\u79cd\u901a\u8fc7\u6291\u5236VEGF-A\u548cPDGF-B\u800c\u53d1\u6325\u4f5c\u7528\u7684DARPin\u836f\u7269\uff09\uff0c\u4ee5\u53ca\u5176\u5b83DARPin\u5316\u5408\u7269\u7684\u9009\u62e9\u6743\uff0c\u534f\u8bae\u5546\u5b9a\u7684\u9884\u4ed8\u6b3e\u4e3a6,250\u4e07\u7f8e\u5143\uff0c\u5206\u671f\u4ed8\u6b3e\u548c\u7279\u8bb8\u4f7f\u7528\u8d39\u9ad8\u8fbe14\u4ebf\u7f8e\u5143\u3002<\/span><\/p>\n


<\/p>\n

Processa \u5236\u836f\u516c\u53f8\u884c\u4f7f\u4e86\u5bf9Concert \u5236\u836f\u516c\u53f8\u7684CTP-499(\u73b0\u5728\u53ebPCS-499)\u7684\u7279\u8bb8\u4f7f\u7528\u9009\u62e9\u6743\uff0c\u8fd9\u662f\u4e00\u79cd\u53e3\u670d\u78f7\u9178\u4e8c\u916f\u9176\u6291\u5236\u5242\uff0c\u7528\u4e8e\u6cbb\u7597\u7c7b\u8102\u8d28\u6e10\u8fdb\u6027\u574f\u6b7b\u548c\u653e\u7597\u7684\u526f\u4f5c\u7528\u3002\u4f5c\u4e3a\u56de\u62a5\uff0cConcert\u5c06\u83b7\u5f97Processa\u516c\u53f8800\u4e07\u7f8e\u5143\u7684\u80a1\u7968\u3002<\/span><\/p>\n


<\/p>\n

Janssen\u751f\u7269\u6280\u672f\u516c\u53f8\u51b3\u5b9a\u4ee575\u4e07\u7f8e\u5143\u7684\u4ef7\u683c\u83b7\u5f97Nuevolution\u516c\u53f8\u7684\u6297\u611f\u67d3\u9879\u76ee\u6388\u6743\u30022015\u5e7410\u6708\uff0c\u53cc\u65b9\u7b7e\u7f72\u4e86\u4e00\u9879\u6d89\u53ca\u5c0f\u5206\u5b50\u5316\u5408\u7269\u836f\u7269\u53d1\u73b0\u534f\u8bae\uff0c\u8be5\u5316\u5408\u7269\u662f\u9488\u5bf9\u764c\u75c7\u3001\u4f20\u67d3\u75c5\u548c\u708e\u6027\u75be\u75c5\u6cbb\u7597\u7684\u591a\u4e2a\u9776\u70b9\uff0c\u968f\u540e\uff0c\u8be5\u534f\u8bae\u4e8e2016\u5e74\u548c2017\u5e74\u5f97\u4ee5\u5ef6\u5c55\u3002<\/span><\/p>\n

 <\/span><\/p>\n

Domp\u00e9\u9009\u62e9\u5c06\u5176\u62e5\u6709\u7684MolMed\u516c\u53f8\u7684nalotimagene carmaleucel\uff08\u662f\u4e00\u79cd\u80f8\u82f7\u6fc0\u9176\u7ec6\u80de\u7597\u6cd5\uff09\u76ee\u524d\u7684\u5e02\u573a\u6269\u5c55\u5230\u745e\u58eb\u3001\u571f\u8033\u5176\u548c\u6fb3\u5927\u5229\u4e9a\u3002\u8fd9\u5bb6\u610f\u5927\u5229\u516c\u53f8\u57282017\u5e74\u4ea4\u6613\u540e\u5df2\u7ecf\u5728\u6b27\u6d32\u7ecf\u6d4e\u533a\uff08EEA\uff09\u62e5\u6709\u8be5\u836f\u7269\u7684\u6743\u5229\u3002MolMed\u516c\u53f8\u6709\u8d44\u683c\u83b7\u5f974350\u4e07\u6b27\u5143(\u7ea6\u54084780\u4e07\u7f8e\u5143)\u7684\u6b3e\u9879\u3002<\/span><\/p>\n


<\/p>\n

\u4eca\u5e742\u6708\uff0cJanssen\u516c\u53f8\u4e0eMacrogenics\u516c\u53f8\u4e4b\u95f4\u8fbe\u6210\u7684\u4ef7\u503c7\u4ebf\u7f8e\u5143\u7684\u3001\u6db5\u76d6duvortuxizumab\uff08\u4e00\u79cd\u7528\u4e8e\u591a\u79cdB\u7ec6\u80de\u6076\u6027\u80bf\u7624\u7684\u4eba\u6e90\u5316CD19 x CD3\u53cc\u7279\u5f02\u6027DART\u86cb\u767d\uff09\u7684\u534f\u8bae\u4e4b\u7ec8\u6b62\uff0c\u5f00\u59cb\u751f\u6548\uff0c\u8fd9\u9879\u7ec8\u6b62\u662f2017\u5e748\u6708\u516c\u544a\u7684\u3002\u7531\u4e8e\u6cbb\u7597\u76f8\u5173\u7684\u795e\u7ecf\u6bd2\u6027\u6570\u636e\uff0c\u8be5\u9879\u76ee\u76841\u671f\u7814\u7a76\u5df2\u7ecf\u4e2d\u65ad\u3002<\/span><\/p>\n


<\/p>\n

\u672c\u5b63\u5ea6\uff0cTeva\u51b3\u5b9a\u7ec8\u6b62\u4e0eXenon\u548cSosei\u7684\u5b50\u516c\u53f8Heptares(\u54088\u4ebf\u591a\u7f8e\u5143)\u7684\u4e24\u7b14\u72ec\u7acb\u4ea4\u6613\uff0c\u539f\u56e0\u662f\u836f\u7269\u6295\u8d44\u7ec4\u5408\u7684\u4f18\u5148\u6b21\u5e8f\u4ee5\u53ca\u4e0e2017\u5e7412\u6708\u5ba3\u5e03\u7684\u91cd\u7ec4\u8ba1\u5212\u6709\u5173\u3002Teva\u5c06\u6297\u504f\u5934\u75db\u964d\u9499\u7d20\u57fa\u56e0\u76f8\u5173\u80bd(CGRP)\u62ee\u6297\u5242(\u5305\u62ec\u5148\u5bfc\u5019\u9009\u836fHTL-0022562)\u7684\u5168\u90e8\u6743\u5229\u8fd4\u8fd8\u7ed9Sosei\u516c\u53f8\u3002\u4e24\u5bb6\u516c\u53f8\u662f2017\u5e745\u6708\u7b7e\u7f72\u7684\u8be5\u534f\u8bae\uff0c\u9884\u4ed8\u8d39\u7528\u4e3a1000\u4e07\u7f8e\u5143\uff0c\u5206\u671f\u4ed8\u6b3e\u4e3a4\u4ebf\u7f8e\u5143\u3002Teva\u516c\u53f8\u548cXenon\u516c\u53f8\u4e5f\u7ec8\u6b62\u4e86\u4ed6\u4eec2012\u5e74\u7b7e\u7f72\u76843.76\u4ebf\u7f8e\u5143\u7684\u534f\u8bae\uff0c\u8be5\u534f\u8bae\u6d89\u53caXenon\u7684funapide\uff0c\u8fd9\u662f\u4e00\u79cdNav 1.7\u548cNav 1.8\u94a0\u901a\u9053\u6291\u5236\u5242\uff0c\u7528\u4e8e\u6cbb\u7597\u795e\u7ecf\u6027\u75bc\u75db\u3002Teva\u5c06\u628a100\u4e07\u80a1\u7968\u548c\u77e5\u8bc6\u4ea7\u6743\u5f52\u8fd8\u7ed9Xenon\u516c\u53f8\u3002\u4f5c\u4e3a\u4ea4\u6362\uff0c\u5982\u679c\u8be5\u4ea7\u54c1\u53ef\u4ee5\u5546\u4e1a\u5316\uff0cXenon\u516c\u53f8\u5c06\u652f\u4ed8\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/span><\/p>\n


<\/p>\n

\u56e0\u585e\u7279\u516c\u53f8\uff08Incyte\uff09\u548c\u6c5f\u82cf\u6052\u745e\u516c\u53f8\u51b3\u5b9a\u7ec8\u6b62\u4ed6\u4eec\u4e4b\u95f4\u76847.95\u4ebf\u7f8e\u5143\u7684\u5408\u4f5c\u5173\u7cfb\uff0c\u8be5\u5408\u4f5c\u5173\u7cfb\u59cb\u4e8e2015\u5e749\u6708\u3002\u8be5\u4e2d\u56fd\u516c\u53f8\u91cd\u65b0\u83b7\u5f97\u4e86\u6297\u764c\u91cd\u7ec4\u4eba\u6e90\u5316\u6297\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\uff08PD\uff09-1\u5355\u514b\u9686\u6297\u4f53SHR-1210\u548c\u5907\u7528\u5316\u5408\u7269\u3002\u6052\u745e\u8ba1\u5212\u5728\u7f8e\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u8fdb\u4e00\u6b65\u5f00\u53d1\u8be5\u6297\u4f53\u3002<\/span><\/p>\n


<\/p>\n

\u7ee7\u8303\u5c14\u8482\u65af\u516c\u53f8\uff08Versartis\uff09\u7684\u7d22\u9a6c\u74e6\u62c9\u5766\uff08somavaratan\uff09\u76843\u671f\u901f\u7387\u8bd5\u9a8c\u672a\u80fd\u6ee1\u8db3\u513f\u7ae5\u751f\u957f\u6fc0\u7d20\u7f3a\u4e4f\u75c7\u60a3\u8005\u7684\u4e3b\u8981\u7ec8\u70b9\u540e\uff0c\u65e5\u672c\u5e1d\u4eba\u516c\u53f8\uff08Teijin\uff09\u7ec8\u6b62\u4e862016\u5e748\u6708\u4e0e\u8303\u5c14\u8482\u65af\u516c\u53f8\u7b7e\u7f72\u7684\u4ef7\u503c1.65\u4ebf\u7f8e\u5143\u7684\u534f\u8bae\u3002\u4e0e\u6b64\u540c\u65f6\uff0c\u5728\u4e24\u5bb6\u516c\u53f8\u7684\u53d1\u5c55\u6218\u7565\u51fa\u73b0\u5206\u6b67\u540e\uff0c\u8fd9\u5bb6\u65e5\u672c\u516c\u53f8\u8fd8\u5c06\u5176\u7528\u4e8e\u8111\u5352\u4e2d\u548c\u521b\u4f24\u6027\u8111\u635f\u4f24\u6cbb\u7597\u76842\u671f\u5f02\u57fa\u56e0\u7ec6\u80de\u7597\u6cd5SB-623\u7684\u6743\u5229\uff0c\u5f52\u8fd8\u7ed9\u4e86SanBio\u516c\u53f8\u3002<\/span><\/p>\n


<\/p>\n

\u5728EOS-200271\u8111\u764c\u60a3\u80051\u671f\u7814\u7a76\u51fa\u73b0\u9634\u6027\u6570\u636e\u4e4b\u540e\uff0c\u8f89\u745e\u516c\u53f8\u5c06\u5176\u9488\u5bf9\u5432\u54da\u80fa2,3-\u53cc\u52a0\u6c27\u91761 (IDO1)\u548c\u8272\u6c28\u91782,3-\u53cc\u52a0\u6c27\u9176(TD02)\u3001\u5305\u62ecEOS-200271\u5728\u5185\u7684iTeos\u5316\u5408\u7269\u7684\u5168\u7403\u6743\u5229\uff0c\u5f52\u8fd8\u7ed9\u4e86iTeos\u516c\u53f8\u3002\u8be5\u534f\u8bae\u662f2014\u5e7412\u6708\u7b7e\u7f72\u7684\uff0ciTeos\u516c\u53f8\u6536\u52302400\u4e07\u6b27\u5143\uff08\u7ea6\u54083180\u4e07\u7f8e\u5143\uff09\u7684\u9884\u4ed8\u6b3e\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n
<\/section>\n<\/section>\n
\n
\n
\n
\n

Teva\u51b3\u5b9a\u7ec8\u6b62\u4e0eXenon\u548cSosei\u7684\u5b50\u516c\u53f8Heptares(\u54088\u4ebf\u591a\u7f8e\u5143)\u7684\u4e24\u7b14\u72ec\u7acb\u4ea4\u6613\uff0c\u539f\u56e0\u662f\u836f\u7269\u6295\u8d44\u7ec4\u5408\u7684\u4f18\u5148\u6b21\u5e8f\u4ee5\u53ca\u4e0e2017\u5e7412\u6708\u5ba3\u5e03\u7684\u91cd\u7ec4\u8ba1\u5212\u6709\u5173\u3002<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

2018\u5e74\u7b2c\u4e8c\u5b63\u5ea6\u5c55\u671b<\/span><\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u57282018\u5e74\u7b2c\u4e8c\u5b63\u5ea6\u521d\uff0cCortellis\u7ade\u4e89\u60c5\u62a5\u4e2d\u53c8\u6dfb\u52a0\u4e86\u51e0\u4efd\u4ea4\u6613\u62a5\u544a\u3002\u4eca\u5e744\u6708\u7684\u5934\u51e0\u5929\uff0c\u4e00\u5bb6\u7528\u67d0\u6295\u8d44\u8d22\u56e2\u76843\u4ebf\u7f8e\u5143\u8d44\u91d1\u65b0\u6210\u7acb\u7684\u751f\u7269\u6280\u672f\u516c\u53f8Allogene Therapeutics\uff0c\u901a\u8fc7\u6536\u8d2d\u8f89\u745e(Pfizer)\u516c\u53f8\u7684\u3001\u7528\u4e8e\u6cbb\u7597\u764c\u75c7\u7684\u5f02\u57fa\u56e0\u5d4c\u5408\u6297\u539f\u53d7\u4f53t\u7ec6\u80de(CAR-T)\u6cbb\u7597\u7ec4\u5408\u800c\u731b\u7136\u51b2\u8fdb\u4e86\u751f\u547d\u79d1\u5b66\u4ea4\u6613\u5e02\u573a\u3002\u8fd9\u4e9b\u8d44\u4ea7\u5305\u62ec\u8f89\u745e\u4eceCellectis\u548cServier\u8bb8\u53ef\u83b7\u5f97\u768416\u79cd\u4e34\u5e8a\u524dT-cell\u7597\u6cd5\uff0c\u4ee5\u53ca\u8f89\u745e\u516c\u53f8\u4eceServier\u516c\u53f8(\u4eceCellectis\u516c\u53f8\u83b7\u5f97\u7684\u6392\u4ed6\u6027\u8bb8\u53ef)\u83b7\u5f97\u7684\u5904\u4e8e\u4e34\u5e8a1\u671f\u7684\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u5f02\u57fa\u56e0CAR-T\u7597\u6cd5\u3002\u4f5c\u4e3a\u56de\u62a5\uff0c\u8f89\u745e\u5c06\u6301\u6709Allogene \u516c\u53f825%\u7684\u80a1\u4efd\uff0c\u5177\u4f53\u6570\u989d\u4e0d\u8be6\u3002Allogene\u516c\u53f8\u5c06\u627f\u62c5\u8f89\u745e\u516c\u53f8\u7684\u6240\u6709\u4e49\u52a1\uff0c\u5305\u62ec\u4ef7\u503c28\u4ebf\u7f8e\u5143(\u5373\u6bcf\u4e2a\u6536\u8d2d\u76ee\u6807\u76841.85\u4ebf\u7f8e\u5143\uff0c\u7528\u4e8e15\u4e2a\u76ee\u6807)\u7684Cellectis\u516c\u53f8\u7684\u4ea4\u6613\uff0c\u4ee5\u53caServier\u516c\u53f8\u7684\u534f\u8bae\uff0c\u8be5\u534f\u8bae\u5c06\u4fdd\u7559\u5bf9UCART-19\u7684\u7f8e\u56fd\u4ee5\u5916\u5730\u533a\u7684\u6743\u5229\u3002<\/span><\/p>\n


<\/span><\/p>\n

\n
\n
\n
\n
\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
\n
\n
\n

\u4f1a\u8bae\u9884\u544a<\/span><\/strong><\/span><\/p>\n

2018\u79d1\u777f\u552f\u5b89\u4e2d\u56fd\u5236\u836f\u884c\u4e1a\u5927\u4f1a<\/span><\/strong><\/span><\/p>\n


<\/span><\/strong><\/span><\/p>\n

\u79d1\u777f\u552f\u5b89\u5c06\u4e8e2018\u5e747\u67085-6\u65e5\u5728\u5357\u4eac\u4e3e\u529e\u300a\u8fce\u63a5\u53d8\u9769\uff0c\u62e5\u62b1\u521b\u65b0\u2014\u2014\u4e13\u4e1a\u4fe1\u606f\u63a8\u52a8\u4e2d\u56fd\u836f\u4f01\u7814\u53d1\u65b0\u5e03\u5c40<\/span><\/strong>\u300b<\/span>\u66a8\u79d1\u777f\u552f\u5b89\u7b2c\u4e94\u5c4a\u4e2d\u56fd\u5236\u836f\u884c\u4e1a\u5927\u4f1a\uff0c\u5e0c\u671b\u4e3a\u4e1a\u754c\u540c\u4ec1\u5e26\u6765\u66f4\u591a\u501f\u9274\u4e0e\u601d\u8003\u3002<\/span><\/p>\n

<\/span><\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n
\n
\n
\n

\u957f\u6309\u4e8c\u7ef4\u7801<\/span><\/p>\n

\u4e86\u89e3\u66f4\u591a\u4f1a\u8bae\u8be6\u60c5\uff01<\/span>
<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n


<\/p>\n

\"\u751f\u547d\u79d1\u5b66\u9886\u57df\u503c\u5f97\u5173\u6ce8\u7684\u6388\u6743\u4ea4\u6613\u8bb8\u53ef|2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\"<\/p>\n

\n
\n

\u5173\u4e8e\u79d1\u777f\u552f\u5b89<\/span><\/strong>
<\/span><\/p>\n<\/section>\n<\/section>\n

\n
\n
\n

\u79d1\u777f\u552f\u5b89\uff08Clarivate Analytics\uff09\u662f\u5168\u7403\u4e13\u4e1a\u4fe1\u606f\u63d0\u4f9b\u4e0e\u5206\u6790\u670d\u52a1\u9886\u57df\u7684\u9886\u5bfc\u8005\u3002\u6211\u4eec\u81f4\u529b\u4e8e\u5e2e\u52a9\u5168\u7403\u7684\u5f00\u62d3\u8005\u4eec\uff0c\u5c06\u5947\u601d\u5999\u60f3\u8f6c\u53d8\u4e3a\u98a0\u8986\u6027\u521b\u65b0\uff0c\u52a0\u901f\u521b\u65b0\u4e0e\u56fd\u9645\u5316\u7684\u8fdb\u7a0b\u3002\u901a\u8fc7\u63d0\u4f9b\u5168\u9762\u7684\u77e5\u8bc6\u4ea7\u6743\u4e0e\u79d1\u6280\u4fe1\u606f\u3001\u51b3\u7b56\u652f\u6301\u5de5\u5177\u53ca\u670d\u52a1\uff0c\u6211\u4eec\u4e3a\u5168\u7403\u5ba2\u6237\u7684\u521b\u65b0\u4e0e\u56fd\u9645\u5316\u63d0\u4f9b\u5f3a\u5927\u52a9\u529b\uff0c\u5e2e\u52a9\u653f\u5e9c\u3001\u5b66\u672f\u754c\u3001\u51fa\u7248\u5546\u548c\u4f01\u4e1a\uff1a\u53d1\u73b0\u65b0\u60f3\u6cd5\uff0c\u4fdd\u62a4\u521b\u65b0\uff0c\u76f4\u5230\u6700\u7ec8\u5b9e\u73b0\u5546\u4e1a\u5316\u3002\u79d1\u777f\u552f\u5b89\u65d7\u4e0b\u62e5\u6709\u8bf8\u591a\u4e1a\u754c\u77e5\u540d\u54c1\u724c\uff0c\u5305\u62ecWeb of ScienceTM<\/sup>\u5e73\u53f0\uff08 \u542b\u79d1\u5b66\u5f15\u6587\u7d22\u5f15\uff0c \u5373ScienceCitation IndexTM<\/sup>\uff0c \u7b80\u79f0SCI\uff09\u3001InCitesTM<\/sup>\u5e73\u53f0\u3001Derwent InnovationTM<\/sup>\u5e73\u53f0\u3001\u5fb7\u6e29\u7279\u4e16\u754c\u4e13\u5229\u7d22\u5f15\uff08DerwentWorld Patents IndexTM<\/sup>\uff0c\u7b80\u79f0DWPI\uff09\u3001CortellisTM<\/sup>\u3001CompuMarkTM<\/sup>\u3001MarkMonitor\u00ae<\/sup> \u4ee5\u53caTechstreetTM <\/sup>\u56fd\u9645\u6807\u51c6\u6570\u636e\u5e93\u7b49\u3002\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u79d1\u777f\u552f\u5b89\u4e2d\u56fd\u5b98\u7f51Clarivate.com.cn\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\n

\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u79d1\u777f\u552f\u5b89\u751f\u547d\u79d1\u5b66\u4e0e\u5236\u836f <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u539f\u6587\u4f5c\u8005\uff1aElisabet Cruces \u4e2d\u6587\u7ffb\u8bd1\uff1a\u8df5\u884c\u8005 \u7b80\u4ecb 2018\u5e74\u7b2c\u4e00\u5b63\u5ea6\uff0cCortellis\u7ade\u4e89\u60c5 […]<\/p>\n","protected":false},"author":1,"featured_media":2778,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/2777"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=2777"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/2777\/revisions"}],"predecessor-version":[{"id":2788,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/2777\/revisions\/2788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/2778"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=2777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=2777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=2777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}